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Abstract: The phenomenon of high sugar consumption by tumor cells is known as Warburg effect.
It results from a high glycolysis rate, used by tumors as preferred metabolic pathway even in aerobic
conditions. Targeting the Warburg effect to specifically deliver sugar conjugated cytotoxic compounds
into tumor cells is a promising approach to create new selective drugs. We designed, synthesized, and
analyzed a library of novel 6-S-(1,4-naphthoquinone-2-yl)-d-glucose chimera molecules (SABs)—novel
sugar conjugates of 1,4-naphthoquinone analogs of the sea urchin pigments spinochromes, which
have previously shown anticancer properties. A sulfur linker (thioether bond) was used to prevent
potential hydrolysis by human glycoside-unspecific enzymes. The synthesized compounds exhibited
a Warburg effect mediated selectivity to human prostate cancer cells (including highly drug-resistant
cell lines). Mitochondria were identified as a primary cellular target of SABs. The mechanism
of action included mitochondria membrane permeabilization, followed by ROS upregulation and
release of cytotoxic mitochondrial proteins (AIF and cytochrome C) to the cytoplasm, which led to the
consequent caspase-9 and -3 activation, PARP cleavage, and apoptosis-like cell death. These results
enable us to further clinically develop these compounds for effective Warburg effect targeting.
Keywords: prostate cancer; thioglucoside conjugates; natural products; sea urchins; glucose uptake
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1. Introduction
Chemotherapy remains an important treatment component for the vast majority of cancer patients.
However, a lack of selectivity for tumor cells over normal cells frequently results in insufficient drug
concentrations in the malignant tissue, systemic toxicity, and the development of drug resistance.
Therefore, inexorable efforts have been made to develop targeted therapies allowing the release of
cytotoxic activity in the region of interest while sparing healthy tissue. Potential therapeutic targets
include cell surface antigens, growth receptors, key regulators of cellular signal transduction, and DNA
repair defects [1]. Antibody drug conjugates (ADCs) consisting of an antibody linked to a biological
active payload are under intensive investigation and first drugs are available in clinics, e.g., gemtuzumab
ozogamicin in acute myeloid leukemia or brentuximab vedotin in relapsed Hodgkin´s lymphoma [2].
In urothelial carcinoma, nectin-4-targeted enfortumab vedotin has been recently accepted for priority
review by the FDA [3]. On a similar note, radioisotope conjugated targeting antibodies are developed
for imaging and radioimmunotherapy strategies. In fact, PSMA-ligand therapy with PSMA-linked
α- or β-emitters are evaluated in clinical trials in prostate cancer and are applied to patients in
every day′s routine on individual bases [4]. Additional targeted therapies in prostate cancer include
androgen-receptor (AR) targeting drugs such as abiraterone acetate, apalutamide, or enzalutamide as
well as PARP-inhibitors in patients with DNA-repair defects [5].
Targeting the Warburg effect is an interesting novel treatment approach utilizing an increased
sugar uptake of cancer cells to incorporate sugar conjugated cytotoxic compounds into tumor
cells [6,7]. The high sugar demand of tumor cells results from the predominantly used metabolic
pathway of glycolysis—even in aerobic conditions—which is energetically less efficient than oxidative
phosphorylation found in healthy cells [8]. Thus, an overexpression of glycolytic enzymes in cytoplasm
and glucose transporters (GLUTs) on the surface of cancer cells is frequently found in tumor cells in
order to comply with the high sugar consumption [6,7].
Consequently, new compounds targeting the Warburg effect have been developed. In fact, sugar
conjugates of docetaxel, busulfan, paclitaxel, and chlorambucil were found to be more selective to
cancer cells in comparison with the non-conjugated “mother” molecules (reviewed in [6]). Furthermore,
a glycosylated derivative of the alkylating agent ifosforamide—glufosfamide—has successfully passed
clinical trials in human pancreatic, brain and CNS, lung cancer and soft tissue sarcoma [9].
More than 50% of the drugs currently available on the market are based on natural compounds
and their synthetic derivatives [10]. Compared to compounds isolated from terrestrial sources,
the marine-derived molecules are less studied [11,12]. At the same time, to date there are ten drugs
approved for clinical use, seven of which are approved for the treatment of cancer and cancer-related
conditions [13,14]. Spinochromes are an important family of polyhydroxynaphthoquinone secondary
metabolites which were found in various sea urchin species. Due to their chemical diversity and
promising pharmacological properties, these compounds attract the attention of scientific community
as a base for development of new drugs [15,16]. Thus, spinochromes have revealed anti-allergic,
anti-hypertensive, anti-diabetic, anti-oxidant, anti-inflammatory, and cardioprotective properties
(reviewed in [15,16]). In general, biological effects of naphthoquinones are associated with generation
of reactive oxygen species and modulation of redox signaling radical reactions [17] being either pro- or
antioxidants or electrophiles [18]. Additionally, naphthazarins (5,8-dihydroxy-1,4-naphthoquinone
derivatives), as well as other polymethoxylated natural and semisynthetic compounds possessing
aromatic core, were reported to be potent anti-mitotic agents. Some of these compounds are capable of
microtubule destabilizing and are therefore highly cytotoxic to cancer cells, representing an attractive
starting point for further design as anticancer agents [19,20]. Thus, trimethyl ether of spinochrome D
(tricrozarin B) inhibits a colony formation of human cancer HeLa S3 cells having IC50 of 0.007µg/mL [21].
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Furthermore, our previous study also showed that methoxy derivatives of 1,4-naphthoquinones exhibit
greater cytotoxicity compared to the corresponding unsubstituted hydroxy analogs [22].
In this study, in continuation of our research on sea urchin pigments [23–25],
we synthesized and analyzed novel sugar conjugates of naturally derived and chemically modified
hydroxyl-1,4-naphthoquinones related to the sea urchin spinochrome pigments. Recently, we identified
several natural 1,4-naphthoquinones to be active in human drug-resistant prostate cancer cells [26] and
were able to synthesize first conjugates withd-glucose possessing in vitro cytotoxic activity [22,26]. In the
current study, we further modified the compounds bearing hydroxy-1,4-naphthoquinone scaffold and
investigated their anticancer properties and the mechanism of action. Thus, to increase the selectivity of
the identified natural 1,4-naphthoquinones via Warburg effect targeting, we conjugated these bioactive
moieties with 6-mercaptoglucose. A glycoside bond is chemically reactive and may be easy degraded
in the living system via enzyme-catalyzed hydrolysis. At the same time, thioglycosides have been
reported to be more resistant to the enzyme-mediated degradation [27]. Therefore, we designed and
synthesized a library of non-glycoside conjugates in order to increase stability of the target compounds
under human body conditions; additionally, we introduced a novel sulfur linker (thioether bond)
to prevent potential hydrolysis by the human glycoside-unspecific enzymes. It is important to note
that an unsubstituted glycoside hydroxy group (at C1 position) is relevant for the stabilizing of the
hydrogen bond interaction between glucose and GLUT-1 and therefore for successful uptake of the
glucose conjugate via this system. In contrast, the conjugation of glucose at C6 position should have a
minimal impact on the GLUT-1 mediated glucose uptake and therefore on the uptake of the synthesized
compounds by the cancer cells. We were able to synthesize the new acetylated (protected) and
non-acetylated (unprotected, containing free-glucose scaffold) thio-conjugates of 1,4-naphthoquinone
and glucose. Human drug-resistant prostate cancer cells were chosen as the main model because of the
known overexpression of GLUT-1. Here, we describe the synthesis of these new conjugates, as well as
their Warburg effect-guided selective anticancer activity and mode of action.
2. Results
2.1. Design and Synthesis of the 6-S-(1,4-Naphthoquinon-2-yl)-d-Glucose Chimera Molecules
In continuation of the research on synthesis of bioactive 1,4-naphthoquinones, capable of selective
activity towards human drug-resistance prostate cancer cells, we designed the chimera molecules
consisting of cytotoxic 1,4-naphthoquinone pharmacophore and 6-thioglucose moiety. These derivatives
are expected to exhibit selective cytotoxicity to cancer cells due to Warburg effect targeting and to be
more stable in human body in comparison with conventional 1,4-naphthoquinone-glucosides due to
the non-glycoside bond and thioether nature of the linker.
Thus, two different synthetic approaches were used for conjugation of naphthoquinones with
6-mercaptoglucose. We applied either: (a) a substitution reaction of halogenoquinones with readily
available tetra-O-acetyl-6-mercaptoglucose in a basic condition (Figure 1A); or (b) an addition reaction
of tetra-O-acetyl-6-mercaptoglucose to juglone, its acetate, or naphthazarin (Figure 1B). This was
followed by saponification of the synthesized acetylated conjugates with MeONa/MeOH (Figure 1C).
Thus, halogenoquinones (Figure 1A) could be readily condensed with tetra-O-acetyl-6-mercaptoglucose
in acetone solution with K2CO3, which resulted in acetylated conjugates SAB-1, -3, -5, -7, -9, -11, -13, -15, -17,
and -19 with the yields of about 60–70%. Note that chloroquinones, having an acidic β-hydroxyl group
in the quinone core, did not react with tetra-O-acetyl-6-mercaptoglucose under the same conditions;
therefore these reactions were performed in DMSO solution (yields ~80%).
As shown previously, reaction of thiols with juglone in EtOH gives exclusively 3-substituted
products [28]. However, we observed that 5-acetyljuglone reacts with thiols giving the 2-substituted
isomer as the main product of the reaction (Figure 1B). Boiling of naphthazarin excess with
mercaptoglucose (molar ration 2:1) mainly gave 2-monosubstituted product SAB-21 (Figure 1B).
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Figure 1. Scheme of synthesis: (A) synthesis of acetylated conjugates SAB-1, -3, -5, -7, -9, -11, -13,
-15, -17, and -19 from halogenoquinones with tetra-O-acetyl-6-mercaptoglucose; (B) synthesis of
the acetylated conjugates SAB-21, -23, and -25 from juglone derivatives and naphthazarin; and (C),
synthesis of the deacetylated (unprotected) conjugates SAB-2, -4, -6, -8, -10, -12, -14, -16, -18, -20, -22,
-24, and -26 from the corresponding acetylated conjugates.
Further saponification of the synthesized acetylated conjugates by MeONa/MeOH led to the
deprotected conjugates SAB-2, -4, -6, -8, -10, -12, -14, -16, -18, -20, -22, -24, and -26 with the yields of
75–82% (Figure 1C). Thus, we were able to synthesize 26 compounds (14 pairs) containing either free
or acetylated 6-thioglucose moiety (Figure 1A–C).
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2.2. Evaluation of Cytotoxicity and Selectivity
First, we evaluated cytotoxic activity of the synthesized compounds in human drug-resistant
prostate cancer PC-3 cells and human prostate non-cancer PNT2 cells. It has been reported that GLUT-1
is a main and the most abundant expressed receptor responsible for the glucose uptake in mammalian
cells [7]. The expression of GLUT-1 in PC-3 was found to be higher in comparison with PNT2 cells
(Figure 2A), thus these lines were considered a suitable model for the screening of Warburg-effect
targeting substances (Figure 2B). Indeed, the selectivity of the conjugates bearing unprotected glucose
residue (and therefore exhibiting increased affinity to GLUT-1) was significantly higher in comparison
with acetylated derivatives (Figure 2C). Thus, we were able to identify one conjugate, SAB-14, to have
a selectivity index (SI) > 2 (Figure 2B). For the further investigations, we selected SAB-14 and -13—the
acetylated derivative revealing a ~10-fold higher cytotoxicity and belonging to the same structural group
as SAB-14. Both compounds were evaluated in five human prostate cancer cell lines known for different
resistance profiles: LNCaP (AR-FL+ and AR-V7−, androgen-dependent, docetaxel-sensitive), 22Rv1
and VCaP (AR-FL+ and AR-V7+, androgen-independent, docetaxel-sensitive), and PC-3 and DU145
(AR-FL− and AR-V7−, androgen-independent, docetaxel-resistant) [29,30]. In addition, five human
non-cancer lines (PNT2, RWPE-1, HEK 293T, MRC-9, and HUVEC) were exposed to the derivates.
In line with our previous results, both compounds were active and selective to human prostate cancer
cells in comparison with non-cancer lines (Figure 2E). Note that SAB-14, bearing unprotected glucose
moiety (Figure 2D), exhibited higher selectivity to the cancer cells (Figure 2E).
Figure 2. Cytotoxicity and selectivity of the synthesized compounds. (A) The Western blot examination
of GLUT-1 expression in human prostate cancer PC-3 versus human prostate non-cancer PNT2 cells and
its quantification. β-actin was used as a loading control (mean ± SEM; n = 3; Student′s t-test). (B) Ratio
of IC50 (PNT2)/IC50 (PC-3) indicated selective cytotoxicity towards human prostate cancer cells versus
human prostate non-cancer cells. “#”, IC50 towards one of the tested cell line was >100 µM; “##”, IC50s
(inhibition concentrations 50%) towards both tested cell line were >100 µM. (C) Pooled selectivity index
(SI) value of acetylated derivatives (Ac-Glc) vs. non-acetylated derivatives (free-Glc) (mean ± SEM;
n ≥ 10; * p < 0.05, Student′s t-test). For each compound, the SI was calculated as IC50 (PNT2)/IC50
(PC-3). (D) Structures of compounds SAB-13 and -14. (E) The mean cytotoxicity of the most promising
compounds SAB-13 and -14 in five prostate cancer (LNCaP, 22Rv1, VCaP, PC-3, and DU145) vs. five
non-cancer (PNT2, RWPE-1, HEK 293T, MRC-9, and HUVEC) cell lines (mean ± SEM; n = 5; Student′s
t-test). Cells were treated for 48 h. The viability was measured by MTT assay.
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2.3. Cytotoxicity Correlates with Glucose Uptake Rate in Prostate Cancer Cells
To examine whether synthesized compounds are able to target the Warburg effect, we accessed the
glucose transporter-1 (GLUT-1) expression in the cells. Note that a mean GLUT-1 mRNA expression
determined by qPCR was 1.6-fold higher in prostate cancer cells (LNCaP, 22Rv1, VCaP, PC-3, and
DU145 cell lines) in comparison with human non-cancer cells (PNT2, RWPE-1, HEK 293T, MRC-9, and
HUVEC cell lines), which correlated with the selectivity of the compounds (Figure 3A). Additionally,
glucose depletion from culture medium resulted in increase of cytotoxic activity of both compounds
(Figure 3B). Moreover, both compounds were able to inhibit glucose uptake in PC-3 cells, which was
observed using two different detection methods (Figure 3C,D). Taken together, our results suggest that
the novel compounds are concurrently ingested by the cells via the same GLUT-1 system as glucose
and thus target the Warburg effect.
Figure 3. Cytotoxicity of the compounds is related to the Warburg effect. (A) The expression of the
glucose transporter 1 mRNA (GLUT-1) in five human prostate cancer cell lines (LNCaP, 22Rv1, VCaP,
PC-3, and DU145) versus four human non-cancer cell lines (PNT2, RWPE-1, HEK 293T, MRC-9, and
HUVEC) (mean ± SEM; n = 5; Student′s t-test). The expression was measured by qPCR. (B) The
viability of PC-3 cells incubated with SAB-13 and -14 in glucose-free (−Glc) or in glucose-containing
media (+Glc, 2 g/L). Cytotoxic activity was measured using MTT test following 24 h of treatment.
(C,D) Concurrent inhibition of glucose uptake by the SAB-13 and -14. PC-3 cells were treated with the
compounds for 24 h and then the glucose uptake was measured using 2-NBDG-based assay either in cell
culture by plate reader (C) or in single cells using flow cytometry technique (D) and then normalized
to cell viability (mean ± SEM; n = 3; * p < 0.05, one-way ANOVA test). Apigenin (Apig), phloretin (Plt),
and cytochalasin B (Ccl-B) were used as positive controls. The viability was measured by MTS assay
(B,C) or by flow cytometry using PI staining (D).
2.4. SAB-13 and -14 Induce Caspase-Dependent Apoptosis
Pro-apoptotic signs such as phosphatidylserine externalization (Figure 4A–C) and PARP cleavage
(Figure 4D) were found in the cells following 48 h treatment with SAB-13 and -14 at the concentrations
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which were close to IC50s in the correspondent cell lines. In addition, cleavage of caspase-3 was
observed (Figure 4D). Co-treatment with pan-caspase inhibitor zVAD antagonized the cytotoxic effects
of SAB-13 and -14, suggesting a caspase-dependent character of the induced apoptosis (Figure 4B).
Furthermore, the cell cycle analysis revealed DNA fragmentation, another pro-apoptotic marker,
detected as sub-G1 peak (Figure 4E). More detailed analysis of the generated data revealed a G2/M-cell
cycle arrest under drug treatment (Figure 4F). This could be at least in part explained with the observed
upregulation of p21 (Figure 4D), which may contribute both to the cycle arrest as well as to the induced
apoptotic cell death [31].
Figure 4. Pro-apoptotic activity of SAB-13 and SAB-14. (A–C,E,F), FACS analysis of the cells
after 48 h treatment. Analysis of apoptosis induction in 22Rv1 (A) and PC-3 cells (B) using
Annexin-V-FITC/propidium iodide (PI) double staining. PC-3 cells were pre-treated with 100 µM of
pan-caspase inhibitor z-VAD(OMe)-fmk (zVAD) for 1 h and then treated with indicated concentrations
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of the drugs for 48 h (B). Viable cells (Annexin-V-FITC(–)/PI(–), LL quadrant) or early apoptotic cells
(Annexin-V-FITC(+)/PI(–), LR quadrant) were quantified using the Cell Quest Pro software (C) (mean
± SEM; n = 3; * p < 0.05, Student′s t-test). (D) Western blotting analysis of the protein expression
in 22Rv1 cells after 48 h of treatment. β-actin was used as a loading control (mean ± SEM; n = 3;
one-way ANOVA test). Anisomycin (Aniso; treatment with 10 µM for 48 h) was used as a positive
control. (E,F) Cell cycle analysis of 22Rv1 cells using PI staining, apoptotic cells were detected as sub-G1
population (E) (mean ± SEM; n = 3; * p < 0.05, one-way ANOVA test).
For this and further examinations, 22Rv1 cells were used as the main model. 22Rv1 cells express
both AR-full length and AR-V7 [32]. The latter mediates resistance of prostate cancer to androgen
receptor targeted therapies such as abiraterone or enzalutamide [33,34]. At the same time, PC-3 cells
are AR-full length- and AR-V7-negative [32] and thus might be less relevant as clinical model for
prostate cancer.
2.5. Effect of SAB-13 on the Proteome of Prostate Cancer Cells
To identify possible processes and molecular targets affected under the treatment, we investigated
changes in proteome of 22Rv1 cells treated with SAB-13, as the most active compounds of the
synthesized panel, at the concentration close to IC50s in the correspondent cell line. The changes in the
protein expression were examined using the LC-MS/MS method in DIA (data independent acquisition)
mode. In total, 2163 proteins were identified and quantified. In total, 253 proteins had 1.5 ≤ fold
change ≤ 1/1.5 and were significantly regulated (p ≤ 0.05) (see Supplementary Materials Table S1).
In fact, upregulation of 104 proteins and downregulation of 149 was detected following the treatment.
The proteomics data was analyzed using the Ingenuity Pathways Analysis software (IPA, QIAGEN
Bioinformatics). Five top protein networks were constructed by IPA and the alteration of five kinases
involved in several pro- and anti-apoptotic processes was predicted (Figure 5A, marked with red circle)
and further validated in functional assays (Figure 5B). Thus, we showed a pronounced activation
of ERK1/2, p38, and Akt kinases upon the treatment, while only slight phosphorylation of MEK1/2
and JNK1/2 kinases was observed (Figure 5B). Thus, alteration of ERK1/2, p38, and Akt may play an
important role in the cellular effect mediated by the synthesized compounds. Note that the regulation
(cleavage) of PARP and caspase (caspase-3), predicted in IPA analysis (Figure 5A), was confirmed
experimentally as well (Figure 4D).
Next, gene ontology analysis and z-score algorithm were used to further predict the effect on
biological processes/target (Figure 5C). Most of the proteins regulated under the treatment were
located in cellular cytoplasm and nucleus, and were identified as enzymes (Figure 5C). Remarkably,
the activity of several upstream regulators playing an important role in prostate cancer development
and progression have been predicted to be affected by SAB-13 (Figure 5D). Among them, the following
are suppressed: E2F3 (transcription factor, its activity was reported to be associated with poor prostate
cancer patients treatment prognosis [35]), ADRB (β-adrenergic receptor, its signaling is involved in the
development of aggressive prostate cancer [36]), BRD4 (kinase, associated with tumor growth and
metastatic potential of prostate cancer [37,38]), 25s proteasome (a promising and relevant target in
a number of human cancers including prostate cancer [39]), and MYC (proto-oncogene, is involved
in initiation and progression of a number of human cancers [40] and drives the development of
the highly aggressive neuroendocrine prostate cancer [36]) (Figure 5D). Additionally, sirtuin and
IL-8 signaling, as well as LXR/RXR and NO and ROS production in macrophages were proposed to
be suppressed, while NER and EIF2 pathway, ILK signaling, and oxidative phosphorylation were
predicted to be activated under the treatment (Figure 5E). At the same time, it is important to note
that predicted activation of KDM5A and XBP1 and suppression of FOXO1 and RB1 were observed.
These alterations may play a possible negative role in prostate cancer as undesirable effects of the drug,
which is described elsewhere. Therefore, these effects should be carefully investigated before further
development of these drugs for in-human trials.
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Figure 5. The effect of SAB-13 on proteome of prostate cancer cells. 22Rv1 cells were treated with SAB-13
(2 µM, 48 h). The changes in proteome identified by LC-MS/MS and later analyzed using Ingenuity
Pathway Analysis (IPA) software and z-score algorithm. (A) Hypothetical protein interaction networks
between regulated proteins and the proteins predicted to be involved in interactions (constructed using
IPA software). (B) Some kinases predicted to be affected under the treatment were further validated by
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Western blotting (marked by red circle). The activation was observed 2 h after the treatment.β-actin was
used as a loading control. The expression phospho-kinases was normalized to the non-phospho-kinases
expression levels (mean ± SEM; n = 3; * p < 0.05; one-way ANOVA test). (C) Gene ontology analysis.
(D) Top upstream targets and the calculated z-score of the effect (activation/inhibition), predicted
by IPA. p-values of overlap is indicated on the graph (significance: p < 0.05, Fischer′s exact test). (E) Top
canonical pathways, predicted by IPA. The target/process is expected to be activated if z-score > 0
(red area) or suppressed if z-score < 0 (green area) (significance: p < 0.05, Fischer′s exact test).
(F) Representative scheme of oxidative phosphorylation. Affected proteins discovered by proteome
analysis are marked with color.
Note that we discovered the alterations of protein components of four (out of five) main protein
complexes located in the inner mitochondrial membrane and involved in the oxidative phosphorylation
(see Table S1). These molecules were identified as parts of Complex I (genes NDUFA4, NDUFS6,
NDUFB1, and NDUFA2), Complex II (gene SDHB), Complex III (gene UQCR10), and Complex IV (genes
COX6B1 and COX17). Therefore, oxidative phosphorylation was predicted to be inhibited/disrupted
in SAB-13-treated cells (z-score = −1.89, p-value = 2.37 × 10−4; Figure 5F).
2.6. SAB-13 and SAB-14 Induce Apoptosis via Mitochondria Targeting
Oxidative phosphorylation (or electron transport-linked phosphorylation) is a metabolic pathway
of nutrients oxidation which takes place in mitochondria and ultimately results in ATP production in
eukaryotic cells [41]. Thus, its disruption predicted by bioinformatical analysis of proteomics data
may indicate mitochondria targeting by SAB-13 and similar compounds. SAB-13 was found to affect
complexes I-IV, essential elements of oxidative phosphorylation machinery, which are located in the
mitochondrial inner membrane. Consequently, we examined the effect of SAB-13 on the mitochondrial
membrane potential (∆Ψm) at the concentration close to IC50. Significant and rapid loss of ∆Ψm
was detected in the prostate cancer cells following both short- (2 h) and long-term (48 h) treatment
(Figure 6A,B). Next, ROS production level was examined, which is known to be closely associated with
mitochondrial integrity [42]. Indeed, a significant increase of the ROS level was observed 2 h after the
treatment, simultaneously with ∆Ψm loss (Figure 6C,D). Moreover, pretreatment with an established
antioxidant N-acetyl-L-cysteine could rescue the cells from the drug-induced apoptosis (Figure 6E).
This confirms the cytotoxic effect of ROS generation under treatment. Additionally, we were able to
show that caspase-9 (but not caspase-3) is activated shortly after treatment at the concentration close
to IC50 (2 h, Figure 6F), whereas caspase-3 cleavage was observed after 48 h treatment (Figure 6G).
Finally, the examination of different subcellular fractions revealed a redistribution of such pro-apoptotic
proteins as cytochrome C and AIF (apoptosis inducing factor) from mitochondria to cytoplasm
(Figure 7). This effect was accompanied by apoptosis induction, as indicated by cleaved PARP and
cleaved caspase-3 as apoptotic markers (Figure 7). In conclusion, induced cancer cell apoptosis was
strongly associated with targeting of mitochondria.
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Figure 6. Effect of SAB-13 and SAB-14 on mitochondrial membrane potential and ROS production.
(A,B) Effect of the drugs on mitochondrial membrane potential (MMP, ∆Ψm). 22Rv1 cells were treated
with the SAB-13 or SAB-14 for indicated time, harvested with trypsin, stained with JC-1, and measured
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by FACS (A), and the cells containing depolarized mitochondria were quantified using the Cell Quest
Pro software (B) (mean ± SEM; n = 3; * p < 0.05, one-way ANOVA test). CCCP (50 µM) was used as a
positive control. (C,D) Effect on ROS production in 22Rv1 cells after 2 h of treatment. Cells were stained
with CM-H2DCFDA, treated with the drugs, harvested, and analyzed by FACS (C), and the ROS level
was quantified using the Cell Quest Pro software (D) (mean ± SEM; n = 3; * p < 0.05, one-way ANOVA
test). H2O2 (200 µM) was used as a positive control. (E) 22Rv1 cells were pre-treated with 1 mM
NaC (N-acetyl-l-cysteine) for 1 h and then co-treated with the investigated drugs for 48 h FBS- and
glucose-free media. Cell viability was measured by MTT assay, treatment time was 48 h. (F,G), Western
blotting analysis of cleaved caspase-3 and -9 levels in 22Rv1 cells treated with SAB-13 for 2 h (F) or
48 h (G). Anisomycin (Aniso) was used as a positive control. β-actin was used as a loading control
(mean ± SEM; n = 3; one-way ANOVA test).
Figure 7. Quantification of the proteins in mitochondrial, cytoplasmic, and total fractions. 22Rv1 cells
were treated with the drugs for 48 h, the proteins were extracted and fractionated using Cell Fractionation
Kit (abcam). The mitochondrial (Mito), cytoplasmatic (Cyto) or total (Total) fractions were concentrated
and analyzed by Western blotting. Cells treated with carbonyl cyanide 3-chlorophenylhydrazone
(CCCP; 50 µM) were used as a positive control. α-tubulin was used as a loading control, the protein
expression was normalized to α-tubulin expression levels either in cytosolic fraction or in the total
protein lysate (mean ± SEM; n = 3; * p < 0.05; one-way ANOVA test).
3. Discussion
A significant percentage of prostate cancer patients initially respond to targeted (e.g., abiraterone
acetate, enzalutamide, PARP-inhibitors, and PSMA-ligand therapy) or untargeted therapies
(e.g., cabazitaxel, docetaxel, and radium-223) [43]. However, the majority of patients will experience
an increasing loss of sensitivity to standard medications with each additional treatment line [44].
Primary as well as secondary drug-resistance are responsible for the limited treatment success and
poor prognosis of patients suffering from advanced castration resistant prostate cancer (CRPC) [45].
Thus, expression of androgen receptor transcriptional variants of AR (AR-Vs), in particular AR-V7 [33],
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has been identified as an important mechanism of resistance to AR-targeted therapies. In addition,
side effects caused by the damage of non-malignant cells limit the application of standard therapies
in a mostly older and comorbid patient population. Thus, novel therapeutics capable of overcoming
drug resistance while sparing side effects are urgently needed.
Conjugation of the cytotoxic molecule and the moiety, which is responsible for selective delivery
of the active substance to cancer cells may increase specificity of the drug and to reduce its side effects.
In the current study we conjugated bioactive 1,4-naphthoquinone scaffold, which has been previously
shown to exhibit cytotoxic activity in human cancer cell lines, with a glucose moiety via a sulfur
linker at C6 position using simple and effective methods. Note that the generated non-glycoside
bond simplified the chemical synthesis of the compounds. Thus, we recently reported a number of
O-glycosides of 1,4-naphthoquinones to undergo decomposition during the deacetylation step [46].
Moreover, we showed that some S-glycosides can convert into linear or angular tetracycles under
the same conditions [46], whereas no undesired effects or side reactions were observed during the
synthesis described in the current research. Thus, we used either: (i) a substitution reaction of the
halogen atoms in 1,4-naphthoquinone derivatives by a sulfur atom of 6-mercaptoglucose derivative;
or (ii) an addition reaction of 6-mercaptoglucose derivative to juglone, its acetate, or naphthazarin,
followed by saponification of the acetylated conjugates.
This modification resulted in a higher specificity to cancer cells due to Warburg effect targeting
as well as increased water solubility and therefore bioavailability of the synthesized molecules.
An exchange of the ether linker to the thioether linker most likely will provide higher stability of the
compounds in the human body [27] and a greater resistance to the enzymes mediated hydrolysis.
The conjugation at C6 position of glucose molecule ensures the affinity of the synthesized conjugates
to GLUT-1 and therefore its successful cellular uptake via this system. Furthermore, it should provide
additional resistance to glycoside-specific enzymes due to the non-glycoside nature of the bond as well
as novel sulfur linker.
Thus, we could synthesize 14 acetylated derivatives and 14 corresponding
water-soluble unprotected (deacetylated) conjugates. Following a screening of the synthesized
compounds, we chose two most promising candidates. Hence, SAB-14 (6-((6-deoxy-6-S-d-
glucopyranosyl)thio)-5,8-dihydroxy-7-methyl-2,3-dimethoxy-1,4-naphthoquinone) and its
acetylated analog SAB-13 (6-((1,2,3,4-tetra-O-acetyl-6-deoxy-β-d-glucopyranosyl)thio)-5,8-dihydroxy-
7-methyl-2,3-dimethoxy-1,4-naphthoquinone) exhibited selectivity to human prostate cancer cells
and were chosen for further investigations. The selectivity of these drugs was mediated by Warburg
effect. This was confirmed by several experiments, namely correlation of selectivity to cancer cell
lines with increased GLUT-1 expression in these cells, the increased cytotoxicity of the compounds in
the glucose-depleted media, and the ability of the compounds to inhibit glucose uptake by the cells,
which was confirmed with two different methods. Additionally, the compounds bearing unsubstituted
glucose residue (e.g., SAB-14) were generally more selective in comparison with its acetylated analogs
(e.g., SAB-13). This can be explained by the higher affinity of unprotected glucose residue to GLUT-1.
These results strongly suggest the synthesized drugs were taken up by the same system, as glucose,
i.e., glucose transporters (GLUTs).
The mechanism of anticancer activity of the natural 1,4-naphthoquinones and other related
compounds includes generation of free superoxide radicals, which results in DNA damage and may
lead to p53-independent cell death [22,47,48], as well as inhibition of topoisomerase-II [47,49,50].
Consequently, the examination of the mechanisms of anticancer activity of SAB-13 and -14 revealed
an induction of caspase-dependent apoptosis. Additionally, we detected a G2/M arrest of the cancer
cells under drug treatment, which could be related to the observed p21 upregulation in the treated
cells. Pro-apoptotic effects of the synthesized conjugates were accompanied by downregulation
of several anti-apoptotic proteins. Further investigation of the drug-mediated changes in cellular
proteome as well as bioinformatical analysis of the data suggested mitochondria targeting as one
of the central effects of SAB-13. Indeed, we were able to validate this effect in functional assays.
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Thus, SAB-13 is able to promote a generation of cytotoxic ROS and to induce a drop-down of
mitochondrial membrane potential, which resulted in a release of cytotoxic mitochondrial proteins
to cellular cytoplasm, caspases activation and ultimately cancer cell death (Figure 8). In addition,
SAB-13 activated caspase-9 shortly after treatment and prior to caspase-3 (Figure 8). It has been
previously shown that the modification of existing drugs in order to assign them mitochondria-targeting
properties (i.e., conjugation with the mitochondria-specific carrier molecule) significantly increases
their activity towards cancer cells [51,52]. Moreover, these drugs were reported to be able to overcome
the drug resistance to standard medications [51,52]. Despite the upregulated glycolysis (anaerobic
respiration) in cancer cells in comparison to normal tissues, the oxidative phosphorylation (part
of aerobic respiration machinery) was reported to be still active and even upregulated in different
cancer entities [53]. Thus, oxidative phosphorylation has recently been identified as a new promising
target in anticancer therapy promoting the therapeutic potential of the inhibitors of this biochemical
process [41]. In fact, inhibitors of different steps of the oxidative phosphorylation cascade such as
metformin, atovaquone, arsenic trioxide, carboxyamidotriazole, fenofibrate, and lonidamine have
exhibited therapeutic efficacy in a number of clinical and preclinical studies for the treatment of
different cancer types (reviewed in [53]). Thus, the combination of Warburg effect mediated selectivity
and the simultaneous targeting of oxidative phosphorylation/mitochondria in cancer cells makes
the synthesized conjugates promising agents in the therapy of the human CRPC and other cancers.
Ongoing experiments will clarify if oxidative phosphorylation is a primary target of the drugs, or if
the targeting of other mitochondrial components and functions cause a disruption of the oxidative
phosphorylation along with other mitochondrial processes. In vivo experiments are currently in
preparation to validate the above-described in vitro results.
Figure 8. Suggested mechanism of anticancer activity in vitro.
4. Materials and Methods
4.1. Chemistry
4.1.1. General Chemistry (Reagents, Solvents and Equipment)
Reagents and solvents were purchased from Sigma (Taufkirchen, Germany) and Vekton
(St. Petersburg, Russia). The initial quinones were purchased from Sigma or synthesized as described
elsewhere. All reagents, initial quinones, and solvents were of analytical grade and used as received.
The melting points were determined on a Boetius melting-point apparatus (Dresden, Germany) and
are uncorrected. The 1H and 13C NMR spectra were recorded using Bruker Avance-300 (300 MHz),
Bruker Avance III-500 HD (500 MHz), and Bruker Avance III-700 (700 MHz) spectrometers (Bruker
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Corporation, Bremen, Germany) using CDCl3 and DMSO-d6 as the solvents with the signal of the
residual non-deuterated solvent as the internal reference. The progress of reaction was monitored by
thin-layer chromatography (TLC) on Sorbfil plates (IMID, Krasnodar, Russia) using the following solvent
systems as eluents: hexane/benzene/acetone, 3:1:1 (v/v) (System A) and benzene/ethyl acetate/methanol,
7:4:2 (System B). Individual substances were isolated and purified using crystallization, column
chromatography as well as preparative TLC on silica gel (Silicagel 60, 0.040–0.063 mm, Alfa Aesar,
Karlsruhe, Germany) which was preliminarily treated with hydrochloric acid (pH = 2) in order to
reduce a residual adsorption of quinones, followed by drying and activation by heating at 120 ◦C.
The initial quinone 6-chloro-5,8-dihydroxy-2,3-dimethoxy-7-methyl-1,4-naphthoquinone was
synthesized from the commercially available reagents as described below. A solution of diazomethane
in Et2O (0.2 M) was added dropwise to a stirring solution of 6-chloro-2,3,5,8-tetrahydroxy-
7-methyl-1,4-naphthoquinone (299 mg, 1.0 mmol) in 1,4-dioxane (50 mL), until TLC indicated
completion of dimethoxylated product with Rf = 0.70 (system A) formation. The reaction mixture
was evaporated in vacuo and the solid was recrystallized from methanol. Red-brown solid; yield 75%
(224 mg); mp 179-181 ◦C; Rf = 0.70 (A). 1H NMR (CDCl3, 500 MHz) δ: 2.42 (s, 3H, -CH3), 4.12 (s, 3H,
-OCH3), 4.13 (s, 3H, -OCH3), 12.94 (s, 1H, C(8)-OH), 13.04 (s, 1H, C(5)-OH). 13C NMR (125 MHz,
CDCl3) δ: 13.5 (-CH3), 61.7 (2 × -OCH3), 108.0 (C-8a), 108.4 (C-4a), 134.2 (C-6), 139.0 (C-7), 147.6, 148.0,
156.3 (C-5), 159.2 (C-8), 181.8 (C-4), 181.9 (C-1); IR (CHCl3) νmax: 3003, 2954, 2855, 1605, 1457, 1432, 1418,
1401, 1379, 1286, 1188, 1158, 1138, 1113, 1053 cm−1. HRMS (EI): m/z [M −H]− calcd for C13H10ClO6:
297.0171; found: 297.0168.
1,2,3,4-Tetra-O-acetyl-6-deoxy-6-thio-β-D-glucopyranose, used for the synthesis of the conjugates, was
synthesized from the commercially available reagents as described below. Potassium metabisulfite
(4.37 g, 19.65 mmol, 1.5 eq) was added to a refluxing solution of 1,2,3,4-tetra-O-acetyl-6-deoxy-
β-d-glucopyranosyl-6-isothiouronium iodide (7.0 g, 13.1 mmol) in mixture of water (75 mL) and
chloroform (75 mL). The reaction mixture was refluxed for 2 h, cooled to room temperature. The organic
layer was separated. The aqueous layer was extracted with chloroform (2 × 50 mL). The organic layers
were combined, dried over NaSO4, filtered, and the solvent evaporated under vacuum. The residue
was recrystallized from MeOH to give pure crystalline product. White solid; yield 57.4% (2.74 g);
mp 109-111 ◦C; Rf = 0.51 (A). 1H NMR (500 MHz, CDCl3) δ: 1.75 (dd, J = 9.6, 7.5 Hz, 1H, -SH),
2.01 (s, 3H, -COCH3), 2.03 (s, 3H, -COCH3), 2.05 (s, 3H, -COCH3), 2.12 (s, 3H, -COCH3), 2.62 (m, H-6a),
2.71 (m, H-6b), 3.96 (ddd, J = 9.7, 6.5, 3.0 Hz, 1H, H-5), 5.11 (t, J = 9.7 Hz, 1H, H-4), 5.12 (t, J = 9.4 Hz,
1H, H-2), 5.25 (t, J = 9.4 Hz, 1H, H-3), 5.71 (t, J = 8.4 Hz, 1H, H-1). 13C NMR (125 MHz, CDCl3) δ:
20.5 (2 × -COCH3), 20.6 (-COCH3), 20.8 (-COCH3), 25.8 (C-6), 70.3 (C-2), 70.4 (C-4), 72.8 (C-3), 75.0
(C-5), 91.7 (C-1), 169.0 (-COCH3), 169.2 (-COCH3), 169.5 (-COCH3), 170.1 (-COCH3). IR (CHCl3) νmax:
3056, 3006, 1759, 1602, 1429, 1370, 1250, 1192, 1079, 1038 cm−1. HRMS (ESI): m/z [M + Na]+ calcd for
C14H20NaO9S: 387.0720; found: 387.0717.
4.1.2. General Procedure for Synthesis of the Acetylated Conjugates SAB-1, -7, -9, -13, -15, -17, and -19
in Acetone Solution (Figure 1A)
Finely powdered potassium carbonate (0.415 g, 3.0 mmol) was added to a solution of the
correspondent quinone, (1.0 mmol) and tetra-O-acetyl-6-mercaptoglucose (0.368 g, 1.01 mmol) in
acetone (120 mL). The mixture was stirred at room temperature until reaction completed (3 h, controlled
by TLC), acidified with HCl, and concentrated in vacuo. The residue was purified by column
chromatography (silica gel, hexane/acetone, 10:1) to give products 1, 7, 9, 13, 15, 17, and 19.
2-(1,2,3,4-Tetra-O-acetyl-6-deoxy-β-d-glucopyranos-6-ylthio)-5,8-dihydroxy-6,7-dimethyl-1,4-naphthoquinone
(SAB-1). Red solid; yield 406 mg (70%); mp 203–205 ◦C; Rf = 0.33 (A). 1H NMR (CDCl3, 500 MHz) δ:
2.02 (s, 3H, -COCH3), 2.03 (s, 3H, -COCH3), 2.08 (s, 3H, -COCH3), 2.13 (s, 3H, -COCH3), 2.22 (s, 3H,
C(7)-CH3), 2.23 (s, 3H, C(6)-CH3), 3.05 (dd, J = 14.0, 7.0 Hz, 1H, H-6′a), 3.13 (dd, J = 14.0, 3.2 Hz, 1H,
H-6′b), 3.97 (ddd, J = 9.5, 7.0, 3.2 Hz, 1H, H-5′), 5.11 (t, J = 9.5 Hz, 1H, H-4′), 5.14 (dd, J = 9.5, 8.2 Hz,
1H, H-2′), 5.28 (t, J = 9.5 Hz, 1H, H-3′), 5.73 (d, J = 8.2 Hz, 1H, H-1′), 6.75 (s, 1H, H-3), 13.01 (s, 1H,
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C(8)-OH), 13.02 (s, 1H, C(5)-OH). 13C NMR (125 MHz, CDCl3) δ: 12.3 (C(7)-CH3), 12.5 (C(6)-CH3),
20.5 (2 × -COCH3), 20.6 (-COCH3), 20.7 (-COCH3), 32.0 (C-6′), 70.1 (C-2′), 71.0 (C-4′), 72.6 (C-3′),
73.4 (C-5′), 91.5 (C-1′), 108.5 (C-4a), 109.4 (C-8a), 125.6 (C-3), 139.9 (C-7), 142.0 (C-6), 148.6 (C-2),
168.8 (-COCH3), 169.2 (-COCH3), 169.4 (C-5), 169.6 (-COCH3), 170.0 (-COCH3), 170.6 (C-8), 171.8 (C-1),
173.0 (C-4). IR (CHCl3) νmax: 2942, 1760, 1599, 1555, 1431, 1371 cm−1. HRMS (EI): m/z [M + Na]+ calcd
for C26H28O13SNa: 603.1143; found: 603.1142.
2-(1,2,3,4-Tetra-O-acetyl-6-deoxy-β-d-glucopyranos-6-ylthio)-5-hydroxy-3-methyl-1,4-naphthoquinone
(SAB-7). Yellow solid; yield 385 mg (70%); mp 160–161 ◦C; Rf = 0.38 (A). 1H NMR (CDCl3, 500 MHz) δ:
1.62 (s, 3H, -COCH3), 1.97 (s, 3H, -COCH3), 1.98 (s, 3H, -COCH3), 2.05 (s, 3H, -COCH3), 2.36 (s, 3H,
C(3)-CH3), 3.22 (dd, J = 14.8, 2.3 Hz, 1H, H-6′a), 3.54 (dd, J = 14.8, 8.3 Hz, 1H, H-6′b), 3.82 (ddd, J = 9.4,
8.3, 2.3 Hz, 1H, H-5′), 4.98 (t, J = 9.4 Hz, 1H, H-4′), 5.00 (dd, J = 9.4, 8.3 Hz, 1H, H-2′), 5.17 (t, J = 9.4
Hz, 1H, H-3′), 5.49 (d, J = 8.3 Hz, 1H, H-1′), 7.21 (dd, J = 7.2, 2.2, 1H, H-6), 7.56 (t, J = 7.2, 1H, H-7),
7.58 (dd, J = 7.2, 2.2, 1H, H-8), 12.15 (s, 1H, C(5)-OH). 13C NMR (CDCl3, 500 MHz) δ: 14.5 (C(3)-CH3),
19.9 (-COCH3), 20.5 (-COCH3), 20.5 (-COCH3), 20.6 (-COCH3), 33.8 (C-6′), 70.0 (C-2′), 70.6 (C-4′),
72.6 (C-3′), 76.4 (C-5′), 91.5 (C-1′), 114.9 (C-4a), 119.6 (C-8), 123.8 (C-6), 133.0 (C-8a), 135.7 (C-7),
146.4 (C-3), 147.2 (C-2), 161.3 (C-5), 168.6 (-COCH3), 169.1 (-COCH3), 169.4 (-COCH3), 170.0 (-COCH3),
180.2 (C-1), 187.2 (C-4).IR (CHCl3) νmax:3096, 2944, 1760, 1667, 1632; 1599, 1572, 1457, 1430, 1367cm−1.
HRMS (ESI): m/z [M + Na]+ calcd for C25H26O12SNa: 573.1037; found: 573.1040.
2,3-Di(1,2,3,4-tetra-O-acetyl-6-deoxy-β-d-glucopyranos-6-ylthio)-5,8-dihydroxy-6,7-dimethyl-1,4-naphthoquinone
(SAB-9). Red solid; yield 258 mg (65%, recovery of starting quinone was 166 mg (58%)); mp 202–205 ◦C;
Rf = 0.76 (A). 1H NMR (CDCl3, 700 MHz) δ: 1.81 (s, 6H, 2×-COCH3), 1.99 (s, 6H, 2 × -COCH3),
2.00 (s, 6H, 2 × -COCH3), 2.08 (s, 6H, 2 × -COCH3), 2.26 (s, 6H, C(6)-CH3, C(7)-CH3), 3.47 (dd, J = 14.5,
8.7 Hz, 2H, H-6′a, H-6′′a), 3.52 (dd, J = 14.5, 2.4 Hz, 2H, H-6′b, H-6′′b), 4.05 (ddd, J = 9.5, 8.7, 2.4 Hz,
2H, H-5′, H-5′′), 4.96 (t, J = 9.5 Hz, 2H, H-4′, H-4′′), 5.05 (dd, J = 9.5, 8.4 Hz, 2H, H-2′, H-2′′), 5.32 (t,
J = 9.5 Hz, 2H, H-3′, H-3′′), 5.72 (d, J = 8.4 Hz, 2H, H-1′, H-1′′), 13.23 (s, 2H, C(5)-OH, C(8)-OH). 13C
NMR (176 MHz, CDCl3) δ: 12.4 (C(6)-CH3, C(7)-CH3), 20.3 (2×-COCH3), 20.6 (2 × -COCH3), 20.6 (2 ×
-COCH3), 20.7 (2 × -COCH3), 35.4 (C-6′, C-6′′), 70.4 (C-2′, C-2′′), 71.3 (C-4′, C-4′′), 72.5 (C-3′, C-3′′),
75.6 (C-5′, C-5′′), 91.3 (C-1′, C-1′′), 109.3 (C-4a, C-8a), 138.6 (C-6, C-7), 145.5 (C-2, C-3), 161.7 (C-5, C-8),
168.8 (2 × -COCH3), 169.2 (2 × -COCH3), 169.7 (2 × -COCH3), 170.1 (2 × -COCH3), 178.7 (C-1, C-4).
IR (CHCl3) νmax: 3053, 2946, 1759, 1600, 1487, 1427, 1370 cm−1. HRMS (EI): m/z [M + Na]+ calcd for
C40H46O22S2Na: 965.1814;found: 965.1807.
6-(1,2,3,4-Tetra-O-acetyl-6-deoxy-β-D-glucopyranos-6-ylthio)-5,8-dihydroxy-7-methyl-2,3-dimethoxy-1,4-
naphthoquinone (SAB-13). Dark red solid; yield 457 mg (73%); mp 96–98 ◦C; Rf = 0.35 (A). 1H NMR
(CDCl3, 500 MHz) δ: 1.99 (s, 6H, 2 × -COCH3), 2.00 (s, 3H, -COCH3), 2.02 (s, 3H, -COCH3), 2.51 (s, 3H,
-CH3), 3.16 (dd, J = 14.5, 8.1 Hz, 1H, H-6′a), 3.36 (dd, J = 14.5, 2.5 Hz, 1H, H-6′b), 3.71 (ddd, J = 9.5, 8.1,
2.5 Hz, 1H, H-5′), 4.12 (s, 3H, -OCH3), 4.13 (s, 3H, -OCH3), 4.98 (t, J = 9.5 Hz, 1H, H-4′), 5.05 (dd, J = 8.3,
9.5 Hz, 1H, H-2′), 5.17 (t, J = 9.5 Hz, 1H, H-3′), 5.60 (t, J = 8.3 Hz, 1H, H-1′), 13.02 (s, 1H, C(8)-OH),
13.43 (s, 1H, C(5)-OH). 13C NMR (125 MHz, CDCl3) δ: 15.0 (-CH3), 20.5 (3×-COCH3), 20.6 (-COCH3),
34.5 (C-6′), 61.6 (-OCH3), 61.7 (-OCH3), 70.2 (C-2′), 70.9 (C-4′), 72.6 (C-3′), 74.9 (C-5′), 91.4 (C-1′),
107.8 (C-4a), 108.5 (C-8a), 136.7 (C-6), 144.7 (C-7), 147.8 (C-3), 147.9 (C-2), 160.0 (C-8), 161.3 (C-5),
168.6 (-COCH3), 169.2 (-COCH3), 169.5 (-COCH3), 170.0 (-COCH3), 180.7 (C-1), 181.0 (C-4). IR (CHCl3)
νmax: 3698, 3610, 3026, 2947, 1760, 1602, 1558, 1455, 1433, 1392, 1374, 1286, 1250, 1192, 1136, 1114, 1077,
1038 cm−1. HRMS (ESI): m/z [M + Na]+ calcd for C27H30NaO15S: 649.1198; found: 649.1195.
6-(1,2,3,4-Tetra-O-acetyl-6-deoxy-β-d-glucopyranos-6-ylthio)-5,8-dihydroxy-2,3,7-trimethyl-1,4-naphthoquinone
(SAB-15). Dark red solid; yield 421 mg (71%); mp 148–151 ◦C; Rf = 0.52 (A). 1H NMR (CDCl3, 500
MHz) δ: 1.88 (s, 3H, -COCH3), 1.99 (s, 6H, 2 × -COCH3), 2.03 (s, 3H, -COCH3), 2.24 (s, 3H, -CH3),
2.25 (s, 3H, -CH3), 2.46 (s, 3H, -CH3), 3.30 (dd, J = 14.6, 7.5 Hz, 1H, H-6′a), 3.34 (dd, J = 14.6, 3.2 Hz,
1H, H-6′b), 3.77 (ddd, J = 9.6, 7.5, 3.2 Hz, 1H, H-5′), 4.98 (t, J = 9.6 Hz, 1H, H-4′), 5.03 (dd, J = 9.6,
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8.3 Hz, 1H, H-2′), 5.18 (t, J = 9.6 Hz, 1H, H-3′), 5.59 (t, J = 8.3 Hz, 1H, H-1′), 13.34 (s, 1H, C(8)-OH),
13.46 (s, 1H, C(5)-OH). 13C NMR (125 MHz, CDCl3) δ: 12.4 (2×-CH3), 15.1 (-CH3), 20.3 (-COCH3), 20.5
(2×-COCH3), 20.6 (-COCH3), 34.5 (C-6′), 70.2 (C-2′), 70.8 (C-4′), 72.6 (C-3′), 75.4 (C-5′), 91.5 (C-1′), 109.1
(C-4a), 109.4 (C-8a), 140.4 (C-6), 140.8 (C-3), 141.1 (C-2), 146.7 (C-7), 168.6 (-COCH3), 169.2 (-COCH3),
169.5 (-COCH3), 170.1 (-COCH3), 171.3 (C-8), 171.6 (C-1, C-5), 171.9 (C-4). IR (CHCl3) νmax: 3705, 3609,
3026, 2944, 1760, 1600, 1559, 1429, 1396, 1373, 1340, 1302, 1250, 1219, 1192, 1121, 1077, 1039 cm−1.
HRMS (ESI): m/z [M + Na]+ calcd for C27H30NaO13S: 617.1299; found: 617.1297.
6-(1,2,3,4-Tetra-O-acetyl-6-deoxy-β-d-glucopyranos-6-ylthio)-7-ethyl-5,8-dihydroxy-2,3-dimethyl-1,4-
naphthoquinone (SAB-17). Dark red solid; yield 481 mg (79%); mp 179–182 ◦C; Rf = 0.59 (A). 1H NMR
(CDCl3, 500 MHz) δ: 1.15 (t, J = 7.6 Hz, 1H, -CH2CH3), 1.89 (s, 3H, -COCH3), 1.99 (s, 6H, 2 × -COCH3),
2.03 (s, 3H, -COCH3), 2.24 (s, 6H, 2 × -CH3), 3.02 (q, J = 7.6 Hz, 2H, -CH2CH3), 3.30 (dd, J = 14.5, 7.7 Hz,
1H, H-6′a), 3.34 (dd, J = 14.5, 3.0 Hz, 1H, H-6′b), 3.77 (ddd, J = 9.6, 7.7, 3.0 Hz, 1H, H-5′), 4.98 (t, J = 9.6
Hz, 1H, H-4′), 5.04 (dd, J = 9.6, 8.3 Hz, 1H, H-2′), 5.18 (t, J = 9.6 Hz, 1H, H-3′), 5.60 (t, J = 8.3 Hz, 1H,
H-1′), 13.36 (s, 1H, C(8)-OH), 13.49 (s, 1H, C(5)-OH). 13C NMR (125 MHz, CDCl3) δ: 12.4 (2 × -CH3),
13.6 (-CH2CH3), 20.3 (-COCH3), 20.5 (2 × -COCH3), 20.6 (-COCH3), 22.4 (-CH2CH3), 34.5 (C-6′),
70.2 (C-2′), 70.9 (C-4′), 72.6 (C-3′), 75.3 (C-5′), 91.4 (C-1′), 109.2 (C-4a), 109.7 (C-8a), 139.7 (C-6),
140.9 (C-3), 141.3 (C-2), 152.1 (C-7), 168.5 (-COCH3), 169.2 (-COCH3), 169.5 (-COCH3), 170.0 (-COCH3),
170.8 (C-8), 171.7 (C-5), 171.9 (C-1), 172.1 (C-4). IR (CHCl3) νmax: 3668, 3601, 3028, 2937, 2875, 1760,
1600, 1556, 1456, 1372, 1338, 1303, 1282, 1249, 1194, 1124, 1076, 1039 cm−1. HRMS (ESI): m/z [M + Na]+
calcd for C28H32NaO13S: 631.1456; found: 631.1453.
2-(1,2,3,4-Tetra-O-acetyl-6-deoxy-β-d-glucopyranos-6-ylthio)-3,6,7-trichloro-5,8-dihydroxy-1,4-naphthoquinone
(SAB-19). Purple solid; yield 420 mg (64%); mp 156–159 ◦C; Rf = 0.48 (A). 1H NMR (CDCl3, 700 MHz)
δ: 1.79 (s, 3H, -COCH3), 1.99 (s, 3H, -COCH3), 2.00 (s, 3H, -COCH3), 2.06 (s, 3H, -COCH3), 3.39 (dd,
J = 14.7, 2.6 Hz, 1H, H-6′a), 3.66 (dd, J = 14.7, 8.0 Hz, 1H, H-6′b), 3.89 (ddd, J = 9.8, 8.0, 2.6 Hz, 1H,
H-5′), 5.02 (t, J = 9.8 Hz, 1H, H-4′), 5.03 (dd, J = 9.4, 8.4 Hz, 1H, H-2′), 5.20 (t, J = 9.4 Hz, 1H, H-3′),
5.54 (t, J = 8.4 Hz, 1H, H-1′), 12.96 (s, 2H, C(5)-OH, C(8)-OH). 13C NMR (176 MHz, CDCl3) δ: 20.2
(-COCH3), 20.5 (2×-COCH3), 20.6 (-COCH3), 34.6 (C-6′), 70.0 (C-2′), 70.7 (C-4′), 72.5 (C-3′), 75.6 (C-5′),
91.7 (C-1′), 109.5 (C-4a), 109.7 (C-8a), 135.4 (C-6, C-7), 141.3 (C-3), 146.3 (C-2), 159.4 (C-8), 160.0 (C-5),
168.5 (-COCH3), 169.1 (-COCH3), 169.5 (-COCH3), 170.0 (-COCH3), 173.3 (C-4), 177.8 (C-1). IR (CHCl3)
νmax: 3697, 3605, 3026, 2944, 1761, 1616, 1559, 1523, 1404, 1371, 1271, 1248, 1192, 1076, 1041 cm−1.
HRMS (ESI): m/z [M + Na]+ calcd for C24H21Cl3NaO13S: 676.9660; found: 676.9655.
4.1.3. General Procedure for Synthesis of the Acetylated Conjugates SAB-3, -5, and -11 in DMSO
Solution (Figure 1A)
The tetra-O-acetyl-6-mercaptoglucose (0.368 g, 1.01 mmol) and finely powdered potassium
carbonate (0.415 g, 3.0 mmol) was added to a solution of correspondent quinone (1.0 mmol) in DMSO
(20 mL). The mixture was stirred at room temperature until reaction completed (3 h, controlled by TLC),
diluted with H2O (200 mL), acidified with HCl, and extracted with AcOEt (3 × 100 mL). The extract was
washed with water (2 × 50 mL), dried with anhydrous Na2SO4, and concentrated in vacuo. The residue
was purified by column chromatography (silica gel, hexane/acetone, 10:1) to give products 3, 5, and 11.
6-(1,2,3,4-Tetra-O-acetyl-6-deoxy-β-d-glucopyranos-6-ylthio)-2,3,5,8-tetrahydroxy-7-methyl-1,4-naphthoquinone
(SAB-3). Red solid; yield 467 mg (78%); mp 207–211 ◦C; Rf = 0.12 (A). 1H NMR (CDCl3, 500 MHz) δ:
1.99 (s, 3H, -COCH3), 2.00 (s, 6H, 2 × COCH3), 2.02 (s, 3H, -COCH3), 2.49 (s, 3H, C(7)-CH3), 3.16 (dd,
J = 14.5, 8.0 Hz, 1H, H-6′a), 3.33 (dd, J = 14.5, 2.6 Hz, 1H, H-6′b), 3.76 (ddd, J = 9.4, 8.0, 2.6 Hz, 1H, H-5′),
5.00 (t, J = 9.4 Hz, 1H, H-4′), 5.06 (dd, J = 9.4, 8.3 Hz, 1H, H-2′), 5.19 (t, J = 9.4 Hz, 1H, H-3′), 5.62 (d,
J = 8.3 Hz, 1H, H-1′), 6.82 (br.s, 2H, C(2)-OH, C(3)-OH), 12.24 (s, 1H, C(5)-OH), 12.70 (s, 1H, C(8)-OH).
13C NMR (CDCl3, 125 MHz) δ: 15.0 (C(7)-CH3), 20.5 (3×-COCH3), 20.6 (-COCH3), 34.7 (C-6′), 70.2
(C-2′), 70.9 (C-4′), 72.6 (C-3′), 74.9 (C-5′), 91.5 (C-1′), 106.2 (C-8a), 107.0 (C-4a), 136.3 (C-6), 137.8 (C-2 *),
138.0 (C-3 *), 144.3 (C-7), 156.5 (C-8), 157.9 (C-5), 168.7 (-COCH3), 169.2 (-COCH3), 169.5 (-COCH3),
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170.1 (-COCH3), 182.4 (C-4), 182.7 (C-1). IR (CHCl3) νmax: 3432, 2944, 1760, 1693, 1626, 1594, 1556,
1419, 1373, 1310 cm−1. HRMS (ESI): m/z [M + Na]+ calcd for C25H26O15SNa 621.0885; found: 621.0882.
*—The assignment of signal is ambiguous.
7-(1,2,3,4-Tetra-O-acetyl-6-deoxy-β-d-glucopyranos-6-ylthio)-2,5,8-trihydroxy-6-methoxy-1,4-naphthoquinone
(SAB-5). Red solid; yield 461 mg (77%); mp 109–112 ◦C; Rf = 0.20 (A). 1H NMR (CDCl3, 500 MHz)
δ: 1.90 (s, 3H, -COCH3), 1.89 (s, 3H, -COCH3), 1.99 (s, 3H, -COCH3), 2.03 (s, 3H, -COCH3), 3.13 (dd,
J = 14.5, 2.8 Hz, 1H, H-6′a), 3.29 (dd, J = 14.5, 7.7 Hz, 1H, H-6′b), 3.83 (ddd, J = 9.5, 7.7, 2.8 Hz, 1H,
H-5′), 4.22 (s, 3H, C(6)-OCH3), 5.02 (t, J = 9.5 Hz, 1H, H-4′), 5.04 (dd, J = 9.5, 8.3 Hz, 1H, H-2′),
5.19 (t, J = 9.5 Hz, 1H, H-3′), 5.59 (d, J = 8.3 Hz, 1H, H-1′), 6.42 (s, 1H, H-3), 7.39 (br s, 1H, C(2)-OH),
12.65 (s, 1H, C(8)-OH), 13.17 (s, 1H, C(5)-OH). 13C NMR (CDCl3, 125 MHz) δ: 20.4 (-COCH3),
20.5 (2×-COCH3), 20.6 (-COCH3), 33.8 (C-6′), 61.9 (C(6)-OCH3), 70.2 (C-2′), 70.9 (C-4′), 72.6 (C-3′),
75.6 (C-5′), 91.4 (C-1′), 107.6 (C-8a), 109.0 (C-4a), 110.2 (C-3), 126.2 (C-7), 157.0 (C-2), 160.3 (C-6),
160.5 (C-5), 168.3 (C-8), 168.5 (-COCH3), 169.2 (-COCH3), 169.5 (-COCH3), 170.1 (-COCH3), 170.4 (C-1),
180.4 (C-4). IR (CHCl3) νmax: 3514, 3404, 2945, 1760, 1659, 1604, 1553, 1445, 1397, 1370, 1349 cm−1.
HRMS (ESI): m/z [M + Na]+ calcd for C25H26O15SNa 621.0885; found: 621.0881.
7-(1,2,3,4-Tetra-O-acetyl-6-deoxy-β-d-glucopyranos-6-ylthio)-3-ethyl-2,5,8-trihydroxy-6-methoxy-1,4-naphthoquinone
(SAB-11). Red solid; yield 501 mg (80%); mp 167–171 ◦C; Rf = 0.33 (A). 1H NMR (CDCl3, 700 MHz)
δ: 1.13 (t, J = 7.5, 3H, -CH2CH3), 1.93 (s, 3H, -COCH3), 1.98 (s, 3H, -COCH3), 1.99 (s, 3H, -COCH3),
2.02 (s, 3H, -COCH3), 2.62 (q, J = 7.5, 2H, -CH2CH3), 4.17 (s, 3H, C(6)-OCH3), 3.16 (dd, J = 14.2, 2.8 Hz,
1H, H-6′a), 3.24 (dd, J = 14.2, 7.7 Hz, 1H, H-6′b), 3.81 (ddd, J = 9.5, 7.7, 2.8 Hz, 1H, H-5′), 5.02 (t,
J = 9.5 Hz, 1H, H-4′), 5.04 (dd, J = 9.5, 8.2 Hz, 1H, H-2′), 5.18 (t, J = 9.5 Hz, 1H, H-3′), 5.61 (d, J = 8.2 Hz,
1H, H-1′), 7.41 (br s, 1H, C(2)-OH), 12.56 (s, 1H, C(8)-OH), 13.47 (s, 1H, C(5)-OH). 13C NMR (176
MHz, CDCl3) δ: 12.6 (-CH2CH3), 16.2 (-CH2CH3), 20.4 (-COCH3), 20.5 (2×-COCH3), 20.6 (-COCH3),
34.1 (C-6′), 61.7 (C(6)-OCH3), 70.3 (C-2′), 70.9 (C-4′), 72.6 (C-3′), 75.4 (C-5′), 91.4 (C-1′), 106.2 (C-8a),
110.0 (C-4a), 125.3 (C-7), 126.4 (C-3), 153.7 (C-2), 155.3 (C-5), 159.7 (C-6), 162.6 (C-8), 168.5 (-COCH3),
169.2 (-COCH3), 169.5 (-COCH3), 170.0 (-COCH3), 176.8 (C-1), 185.2 (C-4). IR (CHCl3) νmax: 3408, 2976,
2941, 2878, 1760, 1598, 1555, 1460 cm−1. HRMS (EI): m/z [M + Na]+ calcd for C27H30O15SNa: 649.1198;
found: 649.1192.
4.1.4. Procedure for Synthesis of Naphthazarin Derivative SAB-21 (Figure 1B)
Tetra-O-acetyl-6-mercaptoglucose (190 mg, 0.52 mmol) was added to the refluxing solution of
naphthazarin (190 mg, 1.0 mmol) in 30 mL of EtOH during 30 min. The reaction mixture was refluxed
for 1.5 h, concentrated in vacuo. The residue was purified by column chromatography (silica gel,
hexane/acetone, 10:1) to give the product 21. Naphthazarin recovery was 44% (83 mg).
2-(1,2,3,4-Tetra-O-acetyl-6-deoxy-β-d-glucopyranos-6-ylthio)-5,8-dihydroxy-1,4-naphthoquinone (SAB-21).
Purple solid; yield 167 mg (54%); mp 207–210 ◦C; Rf = 0.38 (A). 1H NMR (CDCl3, 500 MHz) δ: 2.02 (s,
6H, -COCH3), 2.03 (s, 3H, -COCH3), 2.08 (s, 3H, -COCH3), 2.13 (s, 3H, -COCH3), 3.02 (dd, J = 14.1,
6.9 Hz, 1H, H-6′a), 3.10 (dd, J = 14.1, 3.2 Hz, 1H, H-6′b), 3.96 (ddd, J = 9.5, 6.9, 3.2 Hz, 1H, H-5′), 5.11 (t,
J = 9.5 Hz, 1H, H-4′), 5.14 (dd, J = 9.5, 8.4 Hz, 1H, H-2′), 5.26 (t, J = 9.4 Hz, 1H, H-3′), 5.71 (t, J = 8.4 Hz,
1H, H-1′), 6.68 (s, 1H, H-3), 7.21 (dd, J = 9.4 Hz, 1H, H-7), 7.27 (dd, J = 9.4 Hz, 1H, H-6), 12.11 (s, 1H,
C(8)-OH), 12.57 (s, 1H, C(5)-OH). 13C NMR (125 MHz, CDCl3) δ: 20.5 (2×-COCH3), 20.6 (-COCH3),
20.7 (-COCH3), 31.9 (C-6′), 70.1 (C-2′), 71.0 (C-4′), 72.5 (C-3′), 73.3 (C-5′), 91.6 (C-1′), 111.1 (C-4a),
111.5 (C-8a), 128.1 (C-3), 128.8 (C-7), 130.8 (C-6), 154.2 (C-2), 158.5 (C-5), 159.4 (C-8), 168.8 (-COCH3),
169.1 (-COCH3), 169.6 (-COCH3), 170.0 (-COCH3), 183.6 (C-1), 183.9 (C-4). IR (CHCl3) νmax: 3695,
3600, 3054, 2928, 1761, 1607, 1577, 1556, 1455, 1409, 1371, 1338, 1240, 1221, 1193, 1109, 1077, 1039 cm−1.
HRMS (ESI): m/z [M + Na]+ calcd for C24H24NaO13S: 575.0830; found: 575.0829.
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4.1.5. General Procedure for Synthesis of Juglone Derivatives 23 and 25 (Figure 1B)
Tetra-O-acetyl-6-mercaptoglucose (0.367 g, 1.01 mmol) was added to a suspension of juglone or
juglone acetate (1.0 mmol) in EtOH (65 mL). The reaction mixture was stirred at room temperature
for 12 h and concentrated in vacuo. The residue was purified by column chromatography (silica gel,
hexane/acetone, 10:1) to give the products 23 and 25.
2-(1,2,3,4-Tetra-O-acetyl-6-deoxy-β-d-glucopyranos-6-ylthio)-8-hydroxy-1,4-naphthoquinone (SAB-23). Yellow
solid; yield 349 mg (65%); mp 188–191 ◦C; Rf = 0.39 (A). 1H NMR (CDCl3, 500 MHz) δ: 2.02 (s, 3H,
-COCH3), 2.03 (s, 3H, -COCH3), 2.07 (s, 3H, -COCH3), 2.12 (s, 3H, -COCH3), 3.00 (dd, J = 14.0, 7.0 Hz,
1H, H-6′a), 3.07 (dd, J = 14.0, 3.2 Hz, 1H, H-6′b), 3.95 (ddd, J = 9.6, 7.0, 3.2 Hz, 1H, H-5′), 5.10 (d,
J = 9.6 Hz, 1H, H-4′), 5.14 (dd, J = 9.5, 8.3 Hz, 1H, H-2′), 5.26 (d, J = 9.5 Hz, 1H, H-3′), 5.71 (d, J = 8.3 Hz,
1H, H-1′), 6.64 (s, 1H, H-3), 7.23 (dd, J = 8.0, 1.5 Hz, 1H, H-7), 7.60 (dd, J = 7.4, 1.5 Hz, 1H, H-5),
7.62 (dd, J = 8.0, 7.4 Hz, 1H, H-6), 11.65 (s, 3H, C(8)-OH). 13C NMR (125 MHz, CDCl3) δ: 20.5 (2 ×
-COCH3), 20.6 (-COCH3), 20.7 (-COCH3), 31.8 (C-6′), 70.1 (C-2′), 71.0 (C-4′), 72.6 (C-3′), 73.3 (C-5′),
91.6 (C-1′), 114.7 (8a), 119.3 (C-5), 123.9 (C-7), 128.7 (C-3), 132.0 (C-4a), 137.1 (C-6), 153.3 (C-2),
161.9 (C-8), 168.8 (-COCH3), 169.1 (-COCH3), 169.6 (-COCH3), 170.0 (-COCH3), 180.8 (C-4), 186.8 (C-1).
IR (CHCl3) νmax: 3700, 3600, 2942, 1761, 1634, 1601, 1562, 1457, 1427, 1369, 1273, 1246, 1194, 1169, 1140,
1078, 1039 cm−1. HRMS (ESI): m/z [M + Na]+ calcd for C24H24NaO12S: 536.0881; found: 536.0880.
2-(1,2,3,4-Tetra-O-acetyl-6-deoxy-β-d-glucopyranos-6-ylthio)-5-acetoxy-1,4-naphthoquinone (SAB-25). Yellow
solid; yield 353 mg (61%); mp 172–175 ◦C; Rf = 0.30 (A). 1H NMR (CDCl3, 500 MHz) δ: 2.02 (s, 6H,
2 × -COCH3), 2.06 (s, 3H, -COCH3), 2.11 (s, 3H, -COCH3), 2.43 (s, 3H, -COCH3′), 2.97 (dd, J = 14.1, 7.1
Hz, 1H, H-6′a), 3.03 (dd, J = 14.1, 3.2 Hz, 1H, H-6′b), 3.93 (ddd, J = 9.6, 7.1, 3.2 Hz, 1H, H-5′), 5.09 (d,
J = 9.6 Hz, 1H, H-4′), 5.12 (dd, J = 9.5, 8.3 Hz, 1H, H-2′), 5.24 (d, J = 9.3 Hz, 1H, H-3′), 5.70 (d, J = 8.3
Hz, 1H, H-1′), 6.54 (s, 1H, H-3), 7.37 (dd, J = 8.0, 1.2 Hz, 1H, H-6), 7.71 (dd, J = 8.0, 7.8 Hz, 1H, H-7),
8.06 (dd, J = 7.8, 1.3 Hz, 1H, H-8). 13C NMR (125 MHz, CDCl3) δ: 20.5 (2 × -COCH3), 20.6 (-COCH3),
20.7 (-COCH3), 21.1 (-COCH3′), 31.7 (C-6′), 70.1 (C-2′), 71.0 (C-4′), 72.6 (C-3′), 73.4 (C-5′), 91.5 (C-1′),
123.2 (4a), 125.5 (C-8), 129.3 (C-3), 130.2 (C-6), 133.6 (C-8a), 134.2 (C-7), 149.6 (C-5), 152.2 (C-2), 168.8
(-COCH3), 169.1 (-COCH3), 169.3 (-COCH3), 169.6 (-COCH3), 170.0 (-COCH3), 180.2 (C-4), 181.2 (C-1).
IR (CHCl3) νmax: 3700, 3600, 3016, 2942, 1761, 1671, 1650, 1600, 1566, 1541, 1522, 1457, 1370, 1337, 1247,
1193, 1106, 1078, 1039 cm−1. HRMS (ESI): m/z [M + Na]+ calcd for C26H26NaO13S: 601.0986; found:
601.0982.
4.1.6. General Procedure for Synthesis of Deacetylated Conjugates SAB-2, -4, -6, -8, -10, -12, -14, -16,
-18, -20, -22, -24, and -26 (Figure 1C, Saponification of the Acetylated Conjugates)
A solution of MeONa (0.9 mL of a 1.06 N) in MeOH was added to a stirring suspension of
appropriate acetylated conjugate (0.3 mmol) in anhydrous MeOH (20 mL). The reaction mixture
was stirred for 30 min, neutralized with HCl, concentrated in vacuo. The residue was purified by
preparative TLC (silica gel, benzene/ethyl acetate/methanol 7:4:2 (v/v)) to give the products.
2-(6-Deoxy-d-glucopyranos-6-ylthio)-5,8-dihydroxy-6,7-dimethyl-1,4-naphthoquinone (SAB-2). Red solid;
yield 93 mg (75%); Rf = 0.70 (B). α-anomer: 1H NMR (500 MHz, DMSO-d6) δ: 2.14 (s, 3H, C(7)-CH3),
2.15 (s, 3H, C(6)-CH3), 3.02 (dd, J = 13.3, 8.4 Hz, 1H, H-6′a), 3.09 (dd, J = 9.9, 8.7Hz, 1H, H-4′),
3.19 (dd, J = 9.6, 3.6 Hz, 1H, H-2′), 3.36 (dd, J = 13.3, 2.4 Hz, 1H, H-6′b), 3.45 (dd, J = 9.6, 8.7 Hz,
1H, H-3′), 3.84 (ddd, J = 9.9, 8.4, 2.4 Hz, 1H, H-5′), 4.93 (d, J = 3.6 Hz, 1H, H-1′), 6.90 (s, 1H, H-3),
12.83 (s, 1H, C(8)-OH), 13.10 (s, 1H, C(5)-OH). 13C NMR (125 MHz, DMSO-d6) δ: 12.1 (C(7)-CH3),
12.3 (C(6)-CH3), 32.8 (C-6′), 69.3 (C-5′), 72.3 (C-2′), 72.7 (C-3′), 73.7 (C-4′), 92.6 (C-1′), 107.9 (C-4a),
109.0 (C-8a), 124.7 (C-3), 138.7 (C-7), 141.1 (C-6), 151.3 (C-2), 166.3 (C-5), 167.5 (C-8), 173.4 (C-1),
174.7 (C-4). β-anomer: 1H NMR (500 MHz, DMSO-d6) δ: 2.14 (s, 3H, C(7)-CH3), 2.15 (s, 3H, C(6)-CH3),
2.95 (dd, J = 8.8, 7.7 Hz, 1H, H-2′), 3.03 (dd, J = 14.0, 8.0 Hz, 1H, H-6′a), 3.11 (t, J = 8.8 Hz, 1H, H-4′), 3.17
(t, J = 8.8 Hz, 1H, H-3′), 3.38 (dd, J = 14.0, 2.5 Hz, 1H, H-6′b), 3.40 (ddd, J = 8.8, 8.0, 2.5 Hz, 1H, H-5′),
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4.34 (d, J = 7.7 Hz, 1H, H-1′), 6.89 (s, 1H, H-3), 12.82 (s, 1H, C(8)-OH), 13.10 (s, 1H, C(5)-OH). 13C NMR
(125 MHz, DMSO-d6) δ: 12.1 (C(7)-CH3), 12.3 (C(6)-CH3), 32.6 (C-6′), 73.1 (C-4′), 73.6 (C-5′), 74.8 (C-2′),
76.2 (C-3′), 97.1 (C-1′), 107.9 (C-4a), 109.0 (C-8a), 124.8 (C-3), 138.7 (C-7), 141.1 (C-6), 151.1 (C-2),
166.1 (C-5), 167.3 (C-8), 173.6 (C-1), 174.9 (C-4). HRMS (ESI): m/z [M + Na]+ calcd for C18H20O9SNa:
435.0720; found: 435.0720.
6-(6-Deoxy-d-glucopyranos-6-ylthio)-2,3,5,8-tetrahydroxy-7-methyl-1,4-naphthoquinone (SAB-4). Red solid;
yield 101 mg (78%); Rf = 0.57 (B). α-anomer: 1H NMR (DMSO-d6, 300 MHz) δ: 2.43 (s, 3H, C(7)-CH3),
3.00 (dd, J = 13.7, 8.0 Hz, 1H, H-6′a), 3.08 (t, J = 9.2Hz, 1H, H-4′), 3.14 (dd, J = 9.3, 3.4Hz, 1H, H-2′),
3.38 (t, J = 9.3 Hz, 1H, H-3′), 3.39 (dd, J = 13.7, 2.6 Hz, 1H, H-6′b), 3.71 (ddd, J = 9.3, 8.0, 2.6 Hz, 1H,
H-5′), 4.83 (d, J = 3.4 Hz, 1H, H-1′), 10.53 (br s, 2H, C(2)-OH, C(3)-OH), 12.88 (s, 1H, C(5)-OH), 13.20 (s,
1H, C(8)-OH). 13C NMR (DMSO-d6, 75 MHz) δ: 14.9 (C(7)-CH3), 36.6 (C-6′), 70.8 (C-5′), 72.4 (C-2′),
72.8 (C-3′), 73.2 (C-4′), 92.4 (C-1′), 106.8 (C-8a), 107.7 (C-4a), 136.3 (C-6), 141.3 (C-2*), 141.4 (C-3*), 141.9
(C-7), 154.9 (C-8), 157.1 (C-5), 183.2 (C-4), 183.5 (C-1). β-anomer: 1H NMR (DMSO-d6, 300 MHz) δ:
2.43 (s, 3H, C(7)-CH3), 2.89 (dd, J = 8.8, 7.7Hz, 1H, H-2′), 2.95 (dd, J = 13.3, 8.2 Hz, 1H, H-6′a), 3.02
(t, J = 8.8 Hz, 1H, H-4′), 3.07 (t, J = 8.8 Hz, 1H, H-3′), 3.18 (ddd, J = 8.8, 8.2, 2.2 Hz, 1H, H-5′), 3.35 (dd,
J = 13.3, 2.2 Hz, 1H, H-6′b), 4.24 (d, J = 7.7 Hz, 1H, H-1′), 10.53 (br s, 2H, C(2)-OH, C(3)-OH), 12.88 (s,
1H, C(5)-OH), 13.20 (s, 1H, C(8)-OH).13C NMR (DMSO-d6, 75 MHz) δ: 14.9 (C(7)-CH3), 36.8 (C-6′), 72.8
(C-4′), 74.9 (C-2′), 75.3 (C-5′), 76.4 (C-3′), 97.1 (C-1′), 106.9 (C-8a), 107.8 (C-4a), 135.9 (C-6), 141.3 (C-2*),
141.4 (C-3*), 142.1 (C-7), 154.9 (C-8), 157.1 (C-5), 183.1 (C-4), 183.3 (C-1). HRMS (ESI): m/z [M + Na]+
calcd for C17H18O11SNa: 453.0462; found: 453.0459. *–The assignment of signal is ambiguous.
7-(6-Deoxy-d-glucopyranos-6-ylthio)-2,5,8-trihydroxy-6-methoxy-1,4-naphthoquinone (SAB-6). Red solid;
yield 97 mg (75%), Rf = 0.81(B). α-anomer: 1H NMR (500 MHz, DMSO-d6) δ: 3.06 (t, J = 9.2 Hz, 1H, H-4′),
3.12 (dd, J = 13.0, 8.2 Hz, 1H, H-6′a), 3.13 (dd, J = 9.2, 3.6 Hz, 1H, H-2′), 3.39 (t, J = 9.2 Hz, 1H, H-3′),
3.45 (dd, J = 13.0, 2.6 Hz, 1H, H-6′b), 3.77 (ddd, J = 9.2, 8.2, 2.6 Hz, 1H, H-5′), 4.06 (s, 3H, C(6)-OCH3),
4.84 (d, J = 3.6 Hz, 1H, H-1′), 6.39 (s, 1H, H-3), 11.90 (br s, 1H, C(2)-OH), 12.95 (s, 1H, C(8)-OH),
13.08 (s, 1H, C(5)-OH).13C NMR (125 MHz, DMSO-d6) δ: 35.7 (C-6′), 61.2 (C(6)-OCH3), 70.8 (C-5′),
72.3 (C-2′), 72.8 (C-3′), 73.1 (C-4′), 92.4 (C-1′), 107.1 (C-8a), 109.4 (C-4a), 109.8 (C-3), 130.2 (C-7), 158.9
(C-6), 159.2 (C-2), 165.0 (C-8), 165.7 (C-5), 173.4 (C-1), 174.8 (C-4). β-anomer: 1H NMR (500 MHz,
DMSO-d6) δ: 2.89 (dd, J = 9.0, 7.7 Hz, 1H, H-2′), 3.06 (t, J = 9.0 Hz, 1H, H-4′), 3.09 (t, J = 9.0 Hz, 1H,
H-3′), 3.11 (dd, J = 13.3, 8.0 Hz, 1H, H-6′a), 3.28 (ddd, J = 9.0, 8.0, 2.4 Hz, 1H, H-5′), 3.46 (dd, J = 13.3,
2.4 Hz, 1H, H-6′b), 4.07 (s, 3H, C(6)-OCH3), 4.26 (d, J = 7.7 Hz, 1H, H-1′), 6.38 (s, 1H, H-3), 11.90 (br
s, 1H, C(2)-OH), 12.96 (s, 1H, C(8)-OH), 13.08 (s, 1H, C(5)-OH). 13C NMR (125 MHz, DMSO-d6) δ:
35.5 (C-6′), 61.3 (C(6)-OCH3), 72.7 (C-4′), 74.9 (C-2′), 75.4 (C-5′), 76.4 (C-3′), 97.0 (C-1′), 107.3 (C-8a),
109.5 (C-4a), 109.8 (C-3), 129.7 (C-7), 159.0 (C-6), 159.2 (C-2), 165.3 (C-8), 165.5 (C-5), 173.2 (C-1), 174.0
(C-4). HRMS (ESI): m/z [M + Na]+ calcd for C17H18O11SNa: 453.0462; found: 453.0458.
2-(6-Deoxy-d-glucopyranos-6-ylthio)-5-hydroxy-3-methyl-1,4-naphthoquinone (SAB-8). Red solid; yield
86 mg (75%); Rf = 0.77 (B). α-anomer: 1H NMR (700 MHz, DMSO-d6) δ: 2.24 (s, 3H, C(3)-CH3),
3.03 (dd, J = 9.2, 3.6 Hz, 1H, H-2′), 3.04 (t, J = 9.2 Hz, 1H, H-4′), 3.26 (dd, J = 13.6, 8.0 Hz, 1H, H-6′a),
3.36 (t, J = 9.2 Hz, 1H, H-3′), 3.48 (dd, J = 13.6, 2.5 Hz, 1H, H-6′b), 3.74 (ddd, J = 9.2, 8.0, 2.5 Hz, 1H,
H-5′), 4.81 (d, J = 3.6 Hz, 1H, H-1′), 7.29 (d, J = 8.0, 1H, H-6), 7.50 (d, J = 8.0, 1H, H-8), 7.69 (t, J = 8.0,
1H, H-7), 11.98 (s, 1H, C(5)-OH). 13C NMR (175 MHz, DMSO-d6) δ: 14.4 (C(3)-CH3), 35.7 (C-6′),
71.3 (C-5′), 72.5 (C-2′), 72.6 (C-3′), 72.8 (C-4′), 92.3 (C-1′), 114.8 (C-4a), 119.1 (C-8), 123.4 (C-6), 133.1
(C-8a), 136.1 (C-7), 144.5 (C-3), 148.7 (C-2), 160.2 (C-5), 180.1 (C-1), 186.8 (C-4). β-anomer: 1H NMR
(700 MHz, DMSO-d6) δ: 2.26 (s, 3H, C(3)-CH3), 2.84 (dd, J = 8.2, 7.7 Hz, 1H, H-2′), 3.04 (t, J = 8.2 Hz,
1H, H-4′), 3.07 (t, J = 8.2 Hz, 1H, H-3′), 3.25 (dd, J = 13.3, 7.5 Hz, 1H, H-6′a), 3.28 (ddd, J = 8.2, 7.5,
2.1 Hz, 1H, H-5′), 3.52 (dd, J = 13.3, 2.1 Hz, 1H, H-6′b), 4.26 (d, J = 7.7 Hz, 1H, H-1′), 7.28 (d, J = 8.0, 1H,
H-6), 7.51 (d, J = 8.0, 1H, H-8), 7.71 (t, J = 8.0, 1H, H-7), 11.99 (s, 1H, C(5)-OH).13C NMR (175 MHz,
DMSO-d6) δ: 14.5 (C(3)-CH3), 35.8 (C-6′), 72.4 (C-4′), 74.8 (C-2′), 75.4 (C-5′), 76.2 (C-3′), 97.0 (C-1′),
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114.9 (C-4a), 119.2 (C-8), 123.5 (C-6), 133.0 (C-8a), 136.1 (C-7), 145.2 (C-3), 149.3 (C-2), 160.2 (C-5), 180.1
(C-1), 186.9 (C-4). HRMS (ESI): m/z [M + Na]+ calcd for C17H18O8SNa: 405.0615; found: 405.0618.
2,3-Di(6-deoxy-d-glucopyranos-6-ylthio)-5,8-dihydroxy-6,7-dimethyl-1,4-naphthoquinone (SAB-10). Dark
red solid; yield 142 mg (78%); Rf = 0.04 (B). 1H NMR (500 MHz, DMSO-d6) δ: α-anomer: 2.13 (s, 6H,
(C(6,7)-CH3), 3.06 (t, J = 9.1 Hz, 2H, H-4′), 3.11 (dd, J = 13.2, 8.4 Hz, 2H, H-6a′), 3.12 (dd, J = 9.1,
3.4 Hz, 2H, H-2′), 3.39 (dd, J = 9.1 Hz, 2H, H-3′), 3.44 (dd, J = 13.2, 2.3 Hz, 2H, H-6b′), 3.77 (ddd,
J = 9.1, 8.4, 2.3 Hz, 2H, H-5′), 4.77 (d, J = 3.4 Hz, 2H, H-1′), 13.08 (br s, 2H, C(5,8)-OH); β-anomer:
2.13 (s, 6H, (C(6,7)-CH3), 2.89 (dd, J = 8.2, 7.7Hz, 2H, H-2′), 3.05 (t, J = 8.2 Hz, 2H, H-4′), 3.08 (dd,
J = 13.3, 7.7 Hz, 2H, H-6a′), 3.09 (dd, J = 8.2 Hz, 2H, H-3′), 3.27 (ddd, J = 8.2, 7.7, 2.0 Hz, 2H,H-5′),
3.45 (dd, J = 13.3, 2.0 Hz, 2H,H-6b′), 4.26 (d, J = 7.7 Hz, 2H,H-1′), 13.08 (br s, 2H, C(5,8)-OH); 13C NMR
(125 MHz, DMSO-d6) δ: carbohydrate moiety: α-anomer: 35.9 (C-6′), 70.8 (C-5′), 72.3 (C-2′), 72.8 (C-3′),
73.2 (C-4′), 92.4 (C-1′), β-anomer: 35.7 (C-6′), 72.7 (C-4′), 74.9 (C-2′), 75.4 (C-5′), 76.4 (C-3′), 97.0 (C-1′);
naphthoquinone moiety: 12.5 ((C-6,7)-CH3), 109.1 (C-4a,8a), 138.6 (C-2,3), 147.3 (C-6,7), 161.0 (C-5,8),
177.5 (C-4,8); HRMS (ESI): m/z [M + Na]+ calcd for C24H30O14S2Na: 629.0969; found: 629.0976.
7-(6-Deoxy-d-glucopyranos-6-ylthio)-3-ethyl-2,5,8-trihydroxy-6-methoxy-1,4-naphthoquinone (SAB-12). Red solid;
yield 113 mg (82%); Rf = 0.26 (B). α-anomer: 1H NMR (500 MHz, DMSO-d6) δ: 1.03 (t, J = 7.5, 3H,
-CH2CH3), 2.49 (q, 2H, -CH2CH3), 3.06 (t, J = 9.1 Hz, 1H, H-4′), 3.11 (dd, J = 13.2, 8.4 Hz, 1H, H-6′a),
3.12 (dd, J = 9.1, 3.4Hz, 1H, H-2′), 3.39 (dd, J = 9.1 Hz, 1H, H-3′), 3.44 (dd, J = 13.2, 2.3 Hz, 1H,
H-6′b), 3.77 (ddd, J = 9.1, 8.4, 2.3 Hz, 1H, H-5′), 4.02 (s, 3H,C(6)-OCH3), 4.84 (d, J = 3.4 Hz, 1H,
H-1′), 11.35 (br s, 1H, C(2)-OH), 12.92 (s, 1H, C(8)-OH), 13.51 (s, 1H, C(5)-OH). 13C NMR (125 MHz,
DMSO-d6) δ: 12.6 (-CH2CH3), 15.7 (-CH2CH3), 35.9 (C-6′), 61.0 (C(6)-OCH3), 70.8 (C-5′), 72.3 (C-2′),
72.8 (C-3′), 73.2 (C-4′), 92.4 (C-1′), 107.1 (C-8a), 108.9 (C-4a), 125.6 (C-3), 128.4 (C-7), 156.1 (C-2),
157.3 (C-5), 158.1 (C-6), 164.8 (C-8), 174.3 (C-1), 181.5 (C-4). β-anomer: 1H NMR (500 MHz, DMSO-d6) δ:
1.03 (t, J = 7.5, 3H, -CH2CH3), 2.49 (q, 2H, -CH2CH3), 2.89 (dd, J = 8.2, 7.7Hz, 1H, H-2′), 3.05 (t, J = 8.2 Hz,
1H, H-4′), 3.08 (dd, J = 13.3, 7.7 Hz, 1H, H-6′a), 3.09 (dd, J = 8.2 Hz, 1H, H-3′), 3.27 (ddd, J = 8.2, 7.7,
2.0 Hz, 1H, H-5′), 3.45 (dd, J = 13.3, 2.0 Hz, 1H, H-6′b), 4.02 (s, 3H,C(6)-OCH3), 4.26 (d, J = 7.7 Hz, 1H,
H-1′), 11.35 (br s, 1H, C(2)-OH), 12.92 (s, 1H, C(8)-OH), 13.51 (s, 1H, C(5)-OH).13C NMR (125 MHz,
DMSO-d6) δ: 12.6 (-CH2CH3), 15.7 (-CH2CH3), 35.7 (C-6′), 61.1 (C(6)-OCH3), 72.7 (C-4′), 74.9 (C-2′),
75.4 (C-5′), 76.4 (C-3′), 97.1 (C-1′), 107.2 (C-8a), 108.7 (C-4a), 125.6 (C-3), 127.9 (C-7), 156.1 (C-2),
157.4 (C-5), 158.2 (C-6), 164.6 (C-8), 174.5 (C-1), 181.7 (C-4). HRMS (ESI): m/z [M + Na]+ calcd for
C19H22O11SNa: 481.0775; found: 481.0778.
6-(6-Deoxy-d-glucopyranos-6-ylthio)-5,8-dihydroxy-7-methyl-2,3-dimethoxy-1,4-naphthoquinone (SAB-14).
Purple solid; yield 85 mg (62%); Rf = 0.46 (B). α-anomer: 1H NMR (500 MHz, DMSO-d6) δ: 2.43 (s, 3H,
C(7)-CH3), 3.04 (m, 1H, H-4′), 3.06 (dd, J = 13.6, 7.6 Hz, 1H, H-6′a), 3.11 (m, 1H, H-2′), 3.36 (m, 1H,
H-3′),3.42 (dd, J = 13.6, 2.3Hz, 1H, H-6′b), 3.70 (m, 1H, H-5′), 4.01 (s, 3H,-OCH3), 4.02 (s, 3H,-OCH3),
4.48 (d, J = 6.6Hz, 1H, C(2′)-OH), 4.68 (d, J = 4.8Hz, 1H, C(3′)-OH), 4.81 (t, J = 4.8 Hz, 1H, H-1′),
4.94 (d, J = 5.7 Hz, 1H, C(4′)-OH), 6.27 (d, J = 4.8Hz, 1H, C(1′)-OH), 12.92 (s, 1H, C(8)-OH), 13.21
(s, 1H, C(5)-OH). 13C NMR (125 MHz, DMSO-d6) δ:15.0 (C(7)-CH3), 36.8 (C-6′), 61.4 (2× -OCH3),
70.8 (C-5′), 72.3 (C-2′), 72.8 (C-3′), 73.1 (C-4′), 92.4 (C-1′), 107.8 (C-4a), 108.5 (C-8a), 138.2 (C-6), 142.9
(C-7), 147.8 (C-3), 147.9 (C-2), 158.8 (C-8), 160.6 (C-5), 180.5 (C-1), 180.7 (C-4). β-anomer:1H NMR
(500 MHz, DMSO-d6) δ: 2.43 (s, 3H,C(7)-CH3), 2.88 (m, 1H, H-2′), 3.04 (m, 3H,H-4′,H-3′, H-6′a),
3.20 (m, 1H, H-5′), 3.41 (dd, J = 13.5, 2.1 Hz, 1H, H-6′b), 4.01 (s, 3H,-OCH3), 4.02 (s, 3H,-OCH3),
4.23 (dd, J = 7.6, 6.4 Hz, 1H, H-1′), 4.84 (d, J = 4.8 Hz, 1H, C(2′)-OH), 4.86 (d, J = 4.4 Hz, 1H, C(3′)-OH),
4.99 (d, J = 5.0 Hz, 1H, C(4′-OH), 6.56 (d, J = 6.8 Hz, 1H, C(1′)-OH), 12.92 (s, 1H, C(8)-OH), 13.21 (s, 1H,
C(5)-OH). 13C NMR (125 MHz, DMSO-d6) δ:15.0 (C(7)-CH3), 36.6 (C-6′), 61.4 (2×-OCH3), 72.7 (C-4′),
74.9 (C-2′), 75.3 (C-5′), 76.4 (C-3′), 97.1 (C-1′), 107.8 (C-4a), 108.5 (C-8a), 138.2 (C-6), 142.9 (C-7), 147.8
(C-3), 147.9 (C-2), 158.8 (C-8), 160.6 (C-5), 180.5 (C-1), 180.7 (C-4). HRMS (ESI): m/z [M + Na]+ calcd for
C19H22NaO11S: 481.0775; found: 481.0775.
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2-(6-Deoxy-d-glucopyranos-6-ylthio)-5,8-dihydroxy-3,6,7-trimethyl-1,4-naphthoquinone (SAB-16). Dark red
solid; yield 78 mg (61%); Rf = 0.53 (B). α-anomer: 1H NMR (500 MHz, DMSO-d6) δ: 2.17 (s, 6H,
C(6)-CH3, C(7)-CH3), 2.36 (s, 3H, C(3)-CH3), 3.04 (dd, J = 9.9, 8.7Hz, 1H, H-4′), 3.08 (dd, J = 9.6, 3.6Hz,
1H, H-2′), 3.14 (dd, J = 14.0, 7.7 Hz, 1H, H-6′a), 3.36 (dd, J = 9.6, 8.7 Hz, 1H, H-3′), 3.49 (dd, J = 14.0,
2.6 Hz, 1H, H-6′b), 3.73 (ddd, J = 9.9, 7.7, 2.6 Hz, 1H, H-5′), 4.78 (d, J = 3.6 Hz, 1H, H-1′), 13.23 (s,
1H, C(5)-OH), 13.28 (s, 1H, C(8)-OH). 13C NMR (125 MHz, DMSO-d6) δ: 12.2 (C(6)-CH3, C(7)-CH3),
14.9 (C(3)-CH3), 36.5 (C-6′), 70.9 (C-5′), 72.2 (C-2′), 72.6 (C-3′), 72.9 (C-4′), 92.3 (C-1′), 108.8 (C-8a),
109.0 (C-4a), 139.9 (C-6∗), 140.2 (C-7∗), 142.8 (C-2), 145.1 (C-3), 169.0 (C-5), 169.2 (C-8), 172.3 (C-4),
172.7 (C-1). β-anomer: 1H NMR (500 MHz, DMSO-d6) δ: 2.17 (s, 6H, C(6)-CH3, C(7)-CH3), 2.37 (s, 3H,
C(3)-CH3), 2.87 (dd, J = 8.8, 7.7Hz, 1H, H-2′), 3.04 (t, J = 8.8Hz, 1H, H-4′), 3.07 (t, J = 8.8 Hz, 1H, H-3′),
3.15 (dd, J = 14.0, 7.6 Hz, 1H, H-6′a), 3.25 (ddd, J = 8.8, 7.6, 2.5 Hz, 1H, H-5′), 3.48 (dd, J = 14.0, 2.5 Hz,
1H, H-6′b), 4.23 (d, J = 7.7 Hz, 1H, H-1′), 13.23 (s, 1H, C(5)-OH), 13.29 (s, 1H, C(8)-OH). 13C NMR
(125 MHz, DMSO-d6) δ: 12.2 (C(6)-CH3, C(7)-CH3), 14.9 (C(3)-CH3), 36.3 (C-6′), 72.5 (C-4′), 74.8 (C-2′),
75.3 (C-5′), 76.2 (C-3′), 96.9 (C-1′), 108.9 (C-8a), 109.1 (C-4a), 140.0 (C-6*), 140.2 (C-7*), 142.4 (C-2),
145.4 (C-3), 169.2 (C-5), 169.5 (C-8), 172.1 (C-4), 172.5 (C-1). HRMS (ESI): m/z [M + Na]+ calcd for
C19H22NaO9S: 449.0877; found: 449.0873. *—The assignment of signal is ambiguous.
2-(6-Deoxy-d-glucopyranos-6-ylthio)-5,8-dihydroxy-3-ethyl-6,7-dimethyl-1,4-naphthoquinone (SAB-18). Dark
red solid; yield 82 mg (62%); Rf = 0.56 (B). α-anomer: 1H NMR (500 MHz, DMSO-d6) δ: 1.09 (t,
J = 7.5 Hz, 3H, -CH2CH3), 2.16 (s, 6H, C(6)-CH3, C(7)-CH3), 2.92 (q, J = 7.5 Hz, 2H, -CH2CH3), 3.03 (dd,
J = 9.9, 8.7Hz, 1H, H-4′), 3.10 (dd, J = 9.6, 3.6Hz, 1H, H-2′), 3.17 (dd, J = 14.0, 7.7 Hz, 1H, H-6′a), 3.36
(dd, J = 9.6, 8.7 Hz, 1H, H-3′), 3.50 (dd, J = 14.0, 2.6 Hz, 1H, H-6′b), 3.75 (ddd, J = 9.9, 7.7, 2.6 Hz, 1H,
H-5′), 4.79 (d, J = 3.6 Hz, 1H, H-1′), 13.24 (s, 1H, C(5)-OH), 13.31 (s, 1H, C(8)-OH). 13C NMR (125 MHz,
DMSO-d6) δ: 12.2 (C(6)-CH3, C(7)-CH3), 13.3 (-CH2CH3), 21.9 (-CH2CH3), 36.5 (C-6′), 70.9 (C-5′), 72.2
(C-2′), 72.6 (C-3′), 73.0 (C-4′), 92.3 (C-1′), 108.9 (C-8a), 109.3 (C-4a), 140.2 (C-6*), 140.6 (C-7*), 142.0
(C-2), 149.9 (C-3), 170.5 (C-4*), 170.5 (C-5*), 170.7 (C-8*), 171.6 (C-1). β-anomer: 1H NMR (500 MHz,
DMSO-d6) δ: 1.09 (t, J = 7.5 Hz, 3H, -CH2CH3), 2.16 (s, 6H, C(6)-CH3, C(7)-CH3), 2.87 (dd, J = 8.8,
7.7 Hz, 1H, H-2′), 2.92 (q, J = 7.5 Hz, 2H, -CH2CH3), 3.03 (t, J = 8.8 Hz, 1H, H-4′), 3.07 (t, J = 8.8 Hz,
1H, H-3′), 3.15 (dd, J = 14.0, 7.6 Hz, 1H, H-6′a), 3.26 (ddd, J = 8.8, 7.6, 2.5 Hz, 1H, H-5′), 3.52 (dd,
J = 14.0, 2.5 Hz, 1H, H-6′b), 4.23 (d, J = 7.7 Hz, 1H, H-1′), 13.24 (s, 1H, C(5)-OH), 13.33 (s, 1H, C(8)-OH).
13C NMR (125 MHz, DMSO-d6) δ: 12.2 (2C, C(6)-CH3, C(7)-CH3), 13.3 (-CH2CH3), 21.8 (-CH2CH3),
36.3 (C-6′), 72.7 (C-4′), 74.8 (C-2′), 75.4 (C-5′), 76.2 (C-3′), 96.9 (C-1′), 109.0 (C-8a), 109.3 (C-4a), 140.3
(C-6*), 140.6 (C-7*), 141.5 (C-2), 150.2 (C-3), 170.3 (C-5*), 170.7 (C-4*), 170.9 (C-8*), 171.4 (C-1). HRMS
(ESI): m/z [M + Na]+ calcd for C20H24NaO9S: 463.1033; found: 463.1028. *–The assignment of signal
is ambiguous.
2-(6-Deoxy-d-glucopyranos-6-ylthio)-3,6,7-trichloro-5,8-dihydroxy-1,4-naphthoquinone (SAB-20). Purple
solid; yield 69 mg (47%); Rf = 0.66 (B). α-anomer: 1H NMR (500 MHz, DMSO-d6) δ: 3.10
(m,2H,H-2′,H-4′), 3.39 (t, J = 9.4 Hz, 1H, H-3′), 3.48 (dd, J = 13.4, 7.5 Hz, 1H, H-6′a), 3.69 (dd,
J = 13.5, 2.1 Hz, 1H, H-6′b), 3.81 (m, 1H, H-5′), 4.75 (d, J = 3.7 Hz, 1H, H-1′), 4.78 (s, 1H, C(4′)-OH), 5.05
(br s, 2H, C(2′)-OH, C(3′)-OH), 6.33 (br s, 1H,C(1′)-OH), 12.49 (br s, 2H, C(5)-OH, C(8)-OH). 13C NMR
(125 MHz, DMSO-d6) δ: 36.5 (C-6′), 71.0 (C-5′), 72.2 (C-2′), 72.7 (C-3′), 73.0 (C-4′), 96.9 (C-1′), 111.1
(C-4a), 111.6 (C-8a), 132.3 (C-7), 132.7 (C-6), 138.4 (C-3), 148.6 (C-2), 156.7 (C-8), 157.1 (C-5), 174.0 (C-1),
178.2 (C-4). β-anomer: 1H NMR (500 MHz, DMSO-d6) δ: 2.83 (m, 1H, H-2′), 3.10 (m, 2H,H-3′,H-4′),
3.34 (m, 1H, H-5′), 3.48 (dd, J = 13.4, 7.5 Hz, 1H, H-6′a), 3.71 (dd, J = 13.5, 2.1 Hz, 1H, H-6′b), 4.21 (d,
J = 7.7 1H, H-1′), 4.18 (d, J = 5.2 Hz, 1H, C(4′)-OH), 5.05 (br s, 2H, C(2′)-OH, C(3′)-OH), 6.48 (br s,
1H,C(1′)-OH), 12.49 (br s, 2H, C(5)-OH, C(8)-OH). 13C NMR (125 MHz, DMSO-d6) δ: 36.1 (C-6′), 72.3
(C-4′), 74.7 (C-2′), 75.3 (C-5′), 76.1 (C-3′), 92.4 (C-1′), 110.9 (C-4a), 111.5 (C-8a), 132.2 (C-7), 132.6 (C-6),
138.0 (C-3), 148.6 (C-2), 156.2 (C-8), 156.9 (C-5), 173.3 (C-1), 177.5 (C-4). HRMS (ESI): m/z [M + Na]+
calcd for C16H13Cl3NaO9S: 508.9238; found: 508.9234.
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2-(6-Deoxy-d-glucopyranos-6-ylthio)-5,8-dihydroxy-1,4-naphthoquinone (SAB-22). Purple solid; yield 75 mg
(65%); Rf = 0.48 (B). α-anomer: 1H NMR (500 MHz, DMSO-d6) δ: 3.06 (dd, J = 13.6, 7.6 Hz, 1H, H-6′a),
3.08 (m, 1H, H-4′), 3.18 (m, 1H, H-2′), 3.34 (dd, J = 13.6, 2.1Hz, 1H, H-6′b), 3.44 (m, 1H, H-3′), 3.86
(m, 1H, H-5′), 4.56 (d, J = 6.6Hz, 1H, C(2′)-OH), 4.77 (d, J = 4.9Hz, 1H, C(3′)-OH), 4.92 (t, J = 4.2 Hz,
1H, H-1′), 5.29 (d, J = 5.4Hz, 1H, C(4′)-OH), 6.42 (d, J = 4.7Hz, 1H, C(1′)-OH), 6.87 (s, 1H, H-3), 7.34
(d, J = 9.4 Hz, 1H, H-7), 7.40 (d, J = 9.4Hz, 1H, H-6), 11.86 (s, 1H, C(8)-OH), 12.59 (s, 1H, C(5)-OH).
13C NMR (125 MHz, DMSO-d6) δ: 32.9 (C-6′), 69.1 (C-5′), 72.2 (C-2′), 72.7 (C-3′), 73.6 (C-4′), 92.6 (C-1′),
111.2 (C-4a), 111.7 (C-8a), 127.3 (C-3), 128.6 (C-7), 130.4 (C-6), 157.0 (C-2), 157.6 (C-5), 157.5 (C-8), 183.8
(C-1), 184.2 (C-4). β-anomer: 1H NMR (500 MHz, DMSO-d6) δ: 2.94 (m, 1H, H-2′), 3.04 (dd, J = 13.5,
7.9 Hz, 1H, H-6′a), 3.11 (m, 1H, H-4′), 3.16 (m, 1H, H-3′), 3.35 (dd, J = 13.5, 2.1 Hz, 1H, H-6′b), 3.41 (m,
1H, H-5′), 4.34 (dd, J = 7.5, 6.9 Hz, 1H, H-1′), 4.91 (d, J = 4.8 Hz, 1H, C(2′)-OH), 4.96 (d, J = 4.7 Hz, 1H,
C(3′)-OH), 5.33 (d, J = 5.0 Hz, 1H, C(4′)-OH), 6.71 (d, J = 6.6 Hz, 1H, C(1′)-OH), 6.87 (s, 1H, H-3), 7.34
(d, J = 9.4 Hz, 1H, H-7), 7.40 (d, J = 9.4Hz, 1H, H-6), 11.86 (s, 1H, C(8)-OH), 12.59 (s, 1H, C(5)-OH).
13C NMR (125 MHz, DMSO-d6) δ: 32.6 (C-6′), 73.1 (C-4′), 73.5 (C-5′), 74.8 (C-2′), 76.2 (C-3′), 97.1 (C-1′),
111.2 (C-4a), 111.7 (C-8a), 127.4 (C-3), 128.6 (C-7), 130.4 (C-6), 155.5 (C-2), 156.9 (C-5), 157.5 (C-8), 183.8
(C-1), 184.3 (C-4). HRMS (ESI): m/z [M + Na]+ calcd for C16H16NaO9S: 407.0407; found: 407.0402.
2-(6-Deoxy-d-glucopyranos-6-ylthio)-8-hydroxy-1,4-naphthoquinone (SAB-24). Yellow solid; yield 74 mg
(64%); Rf = 0.46 (B). α-anomer: 1H NMR (500 MHz, DMSO-d6) δ: 2.99 (dd, J = 13.4, 8.2 Hz, 1H, H-6′a),
3.09 (m, 1H, H-4′), 3.18 (m, 1H, H-2′), 3.31 (dd, J = 13.4, 2.6 Hz, 1H, H-6′b), 3.44 (m, 1H, H-3′), 3.86 (m,
1H, H-5′), 4.56 (d, J = 6.6 Hz, 1H, C(2′)-OH), 4.78 (d, J = 5.0 Hz, 1H, C(3′)-OH), 4.92 (t, J = 4.4 Hz, 1H,
H-1′), 5.28 (d, J = 5.3 Hz, 1H, C(4′)-OH), 6.42 (d, J = 4.6 Hz, 1H, C(1′)-OH), 6.81 (s, 1H, H-3), 7.30 (d,
J = 8.4, 0.8 Hz, 1H, H-7), 7.50 (d, J = 7.4, 0.8Hz, 1H, H-5), 7.75 (dd, J = 8.4, 7.4 Hz, 1H, H-6), 11.46 (s, 1H,
C(8)-OH). 13C NMR (125 MHz, DMSO-d6) δ: 32.7 (C-6′), 69.2 (C-5′), 72.2 (C-2′), 72.7 (C-3′), 73.6 (C-4′),
92.5 (C-1′), 114.9 (C-8a), 118.7 (C-5), 123.5 (C-7), 127.7 (C-3), 132.1 (C-4a), 137.3 (C-6), 154.6 (C-2), 160.5
(C-8), 180.4 (C-4), 186.2 (C-1). β-anomer: 1H NMR (500 MHz, DMSO-d6) δ: 2.94 (m, 1H, H-2′), 2.98
(m, 1H, H-4′), 3.03 (dd, J = 13.4, 7.7 Hz, 1H, H-6′a), 3.14 (m, 1H, H-3′), 3.33 (dd, J = 13.4, 2.3 Hz, 1H,
H-6′b), 3.40 (m, 1H, H-5′), 4.33 (dd, J = 7.5, 6.6 Hz, 1H, H-1′), 4.91 (d, J = 4.8 Hz, 1H, C(2′)-OH), 4.96 (d,
J = 4.7 Hz, 1H, C(3′)-OH), 5.33 (d, J = 5.1 Hz, 1H, C(4′)-OH), 6.71 (d, J = 6.6 Hz, 1H, C(1′)-OH), 6.81 (s,
1H, H-3), 7.30 (d, J = 8.4, 0.8 Hz, 1H, H-7), 7.50 (d, J = 7.4, 0.8Hz, 1H, H-5), 7.75 (dd, J = 8.4, 7.4 Hz, 1H,
H-6), 11.46 (s, 1H, C(8)-OH). 13C NMR (125 MHz, DMSO-d6) δ: 32.5 (C-6′), 73.1 ( C-4′), 73.5 (C-5′), 74.8
(C-2′), 76.2 (C-3′), 97.1 (C-1′), 114.9 (C-8a), 118.7 (C-5), 123.5 (C-7), 127.8 (C-3), 132.1 (C-4a), 137.3 (C-6),
154.3 (C-2), 160.5 (C-8), 180.4 (C-4), 186.2 (C-1). HRMS (ESI): m/z [M + Na]+ calcd for C16H16NaO8S:
391.0458; found: 391.0455.
2-(6-Deoxy-d-glucopyranos-6-ylthio)-5-hydroxy-1,4-naphthoquinone (SAB-26). Yellow solid; yield 65 mg
(59%); Rf = 0.46 (B). α-anomer:1H NMR (500 MHz, DMSO-d6) δ: 3.01 (dd, J = 13.4, 8.1 Hz, 1H, H-6′a),
3.08 (m, 1H, H-4′), 3.18 (m, 1H, H-2′), 3.32 (dd, J = 13.4, 2.4Hz, 1H, H-6′b), 3.44 (m, 1H, H-3′), 3.87 (m,
1H, H-5′), 4.56 (d, J = 6.7Hz, 1H, C(2′)-OH), 4.77 (d, J = 4.9Hz, 1H, C(3′)-OH), 4.92 (t, J = 4.2 Hz, 1H,
H-1′), 5.28 (d, J = 5.4Hz, 1H, C(4′)-OH), 6.42 (d, J = 4.8Hz, 1H, C(1′)-OH), 6.81 (s, 1H, H-3), 7.36 (d,
J = 8.4, 1.0 Hz, 1H, H-6), 7.56 (d, J = 7.5, 1.0Hz, 1H, H-8), 7.71 (dd, J = 8.4, 7.5Hz, 1H, H-7), 12.12 (s,
1H, C(5)-OH). 13C NMR (125 MHz, DMSO-d6) δ: 32.9 (C-6′), 69.1 (C-5′), 72.2 (C-2′), 72.7 (C-3′), 73.6
(C-4′), 92.6 (C-1′), 114.4 (C-4a), 119.3 (C-8), 124.8 (C-6), 126.8 (C-3), 131.7 (C-8a), 136.1 (C-7), 156.1 (C-2),
160.5 (C-5), 181.2 (C-1), 186.6 (C-4). β-anomer:1H NMR (500 MHz, DMSO-d6) δ: 2.94 (m, 1H, H-2′),
3.02 (dd, J = 13.4, 7.9 Hz, 1H, H-6′a), 3.10 (m, 1H, H-4′), 3.16 (m, 1H, H-3′), 3.35 (dd, J = 13.4, 2.3 Hz,
1H, H-6′b), 3.41 (m, 1H, H-5′), 4.34 (dd, J = 7.6, 6.6 Hz, 1H, H-1′), 4.91 (d, J = 4.6 Hz, 1H, C(2′)-OH),
4.95 (d, J = 4.8 Hz, 1H, C(3′)-OH), 5.33 (d, J = 5.1 Hz, 1H, C(4′)-OH), 6.70 (d, J = 6.7 Hz, 1H, C(1′)-OH),
6.81 (s, 1H, H-3), 7.36 (d, J = 8.4, 1.0 Hz, 1H, H-6), 7.56 (d, J = 7.5, 1.0Hz, 1H, H-8), 7.71 (dd, J = 8.4,
7.5Hz, 1H, H-7), 12.12 (s, 1H, C(5)-OH). 13C NMR (125 MHz, DMSO-d6) δ: 32.6 (C-6′), 73.1 ( C-4′),
73.5 (C-5′), 74.8 (C-2′), 76.2 (C-3′), 97.1 (C-1′), 114.4 (C-4a), 119.3 (C-8), 124.8 (C-6), 126.9 (C-3), 131.7
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(C-8a), 136.1 (C-7), 155.9 (C-2), 160.5 (C-5), 181.2 (C-1), 186.6 (C-4). HRMS (ESI): m/z [M + Na]+ calcd
for C16H16NaO8S: 391.0458; found: 391.0455. * The assignment of signal is ambiguous.
4.2. Biology
4.2.1. General Biology (Reagents and Antibodies)
Annexin-V-FITC was purchased from BD Bioscience (San Jose, CA, USA). MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) and propidium iodide (PI) from Sigma
(Taufkirchen, Germany). cOmplete™ EASYpacks protease inhibitors cocktail and PhosSTOP™ EASYpacks
– from Roche (Mannheim, Germany). Anisomycin was from NeoCorp (Weilheim, Germany).
z-VAD(OMe)-fmk was from Enzo Life Sciences (Farmingdale, NY, USA). H2O2 was from Carl Roth
(Karlsruhe, Germany). CCCP (2-[2-(3-chlorophenyl)hydrazinylyidene]propanedinitrile) was from Sigma
(Taufkirchen, Germany). JC-1 (5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolylcarbocyanine iodide)
was from AdiloGen Life Science (Epalinges, Switzerland). N-acetylcystein was from MedChemExpress
(Monmouth Junction, NJ, USA). Primary and secondary antibodies used are listed in Table 1.
Table 1. List of antibodies used.
Antibodies Clonality Source Cat.-No. Dilution Manufacturer
anti-AIF mAb rabbit #5318 1:1000 Cell Signaling
anti-Akt pAb rabbit #9272 1:1000 Cell Signaling
anti-Bcl-2 pAb rabbit #2876 1:1000 Cell Signaling
anti-cleaved Caspase-3 mAb rabbit #9664 1:1000 Cell Signaling
anti-cleaved Caspase-9 mAb rabbit #20750 1:1000 Cell Signaling
anti-cytochrome C mAb rabbit #11940 1:1000 Cell Signaling
anti-ERK1/2 mAb mouse #9107 1:2000 Cell Signaling
anti-GLUT1 mAb rabbit #12939 1:1000 Cell Signaling
anti-JNK1/2 mAb rabbit #9258 1:1000 Cell Signaling
anti-MEK1/2 pAb rabbit #9122 1:1000 Cell Signaling
anti-mouse IgG-HRP sheep NXA931 1:10,000 GE Healthcare
anti-p21Waf1/Cip1 mAb rabbit #2947 1:1000 Cell Signaling
anti-p38 mAb rabbit #9212 1:1000 Cell Signaling
anti-PARP pAb rabbit #9542 1:1000 Cell Signaling
anti-phospho-Akt mAb rabbit #4058 1:1000 Cell Signaling
anti-phospho-ERK1/2 mAb rabbit #4377 1:1000 Cell Signaling
anti-phospho-JNK1/2 mAb rabbit #4668 1:1000 Cell Signaling
anti-phospho-MEK1/2 mAb rabbit #2338 1:1000 Cell Signaling
anti-phospho-p38 mAb rabbit #4511 1:1000 Cell Signaling
anti-rabbit IgG-HRP goat #7074 1:5000 Cell Signaling
anti-Survivin pAb rabbit NB500-201 1:1000 Novus
anti-α-Tubulin mAb mouse T5168 1:5000 Sigma-Aldrich
anti-β-Actin-HRP pAb goat sc-1616 1:10,000 Santa Cruz
4.2.2. Cell Lines and Culture Conditions
The human prostate cancer cell lines PC-3, DU145, 22Rv1, and LNCaP, as well as human prostate
non-cancer cell lines RWPE-1 and PNT2 were purchased from ATCC (Manassas, VA, USA). The human
prostate cancer cell line VCaP was purchased from ECACC (Salisbury, UK). HEK 293T (human embryonic
kidney cells), MRC-9 (human fibroblast cells) and HUVEC (human umbilical vascular endothelial cells,
passage 11) were a gift from Prof. Sonja Loges (University Medical Center Hamburg-Eppendorf, Hamburg,
Germany). All the cells had a passage number ≤ 30. Authentification of all cell lines used was recently
performed by commercial service (Multiplexion GmbH, Heidelberg, Germany).
Cells were cultured as monolayers at 37 ◦C in a humidified atmosphere with 5% (v/v) CO2
in the correspondent culture medium: 10% FBS/RPMI medium (RPMI medium supplemented
with GlutamaxTM-I (gibco® Life technologiesTM, Paisley, UK) containing 10% fetal bovine serum
(FBS, gibco® Life technologiesTM) and 1% penicillin/streptomycin (Invitrogen)) for PNT2, LNCaP,
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22Rv1, PC-3, and DU145 and cells; 10% FBS/DMEM medium (DMEM medium supplemented with
GlutamaxTM-I (gibco® Life technologiesTM) containing 10% FBS and 1% penicillin/streptomycin
(gibco® Life technologiesTM)) for VCaP, MRC-9, and HEK 293 cells; Keratinocyte Serum Free Medium
(K-SFM) kit (gibco® Life technologiesTM, Paisley, UK, Cat. #17005-042) supplied with BPE and hEGF
for RWPE-1 cells; and Clonetics® EGMTM-2 SingleQuots® medium (Lonza, Walkersville, MD, USA)
containing 10% FBS for HUVEC cells. Cells were continuously kept in culture for a maximum of 3
months, and were regularly checked for stable phenotype and mycoplasma infection.
4.2.3. MTT Assay
Cell viability was determined by MTT assay. Cells were pre-incubated overnight in 96-well plates
(6 × 103 cells/well in 100 µL/well). Then, the medium was replaced with fresh medium containing the
determined compounds (100 µL/well), and cells were incubated for the indicated time. Next, 10 µL/well
of (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) reagent were added. After 2–4 h of
incubation, the media was aspirated and the plates were dried. Fifty microliters per well of DMSO
were added to each well and the cell viability was measured using Infinite F200PRO reader (TECAN,
Männedorf, Switzerland). Results were calculated by The GraphPad Prism software v. 7.05 (GraphPad
Prism software Inc., La Jolla, CA, USA) and are represented as IC50 of the compounds against control
cells treated with the solvent alone.
4.2.4. Quantitative Real-Time PCR (qPCR)
GLUT-1 gene expression in different cell lines was measured by qPCR. Cells were seeded in
Petri dishes (1 × 106 cells per ø 10 cm dish in 5 mL of media for 22Rv1) in 10% FBS/RPMI media
and incubated overnight. Cells were harvested by scratching, washed, and homogenized using
QIAshredder (Cat. # 79654, QIAGEN, Hilden, Germany). The total RNA was isolated using PureLink®
RNA Mini Kit (Cat. # 12183018A, Invitrogen, Carlsbad, CA, USA) with the on-column DNA digestion
using PureLink™ DNase (Cat. # 12185-010, Invitrogen). RNA was diluted up to 30 µL and 2 µg of
RNA was transcribed into cDNA using Maxima First Strand cDNA Synthesis Kit for RT-qPCR (Cat.
# K1642, Thermo Scientific, Vilnius, Lithuania). qPCR was performed using 2X KAPA SYBR FAST
qPCR Master Mix Optimized for Roche LightCycler 480 (Cat. # KK4609, KAPA biosystems, Worburn,
MA, USA) according to the manufacturer′s recommendations. For each reaction, 20 ng of template
cDNA and 2 pmol of primers were used. The expression of human GLUT-1 and GAPDH genes
were analyzed using primers, purchased from by Eurofins MWG-Biotech AG (Ebersberg, Germany).
Primers sequences and melting temperatures (Tm): GLUT-1: forward AAC TCT TCA GCC AGG
GTC CAC, reverse CAC AGT GAA GAT GAT GAA GAC, Tm = 60 ◦C; GAPDH: forward TGC ACC
ACC AAC TGC TTA, reverse GAG GCA GGG ATG ATG TTC, Tm = 56 ◦C. The PCR conditions were
30 s 95 ◦C, followed by 40 cycles of 15 s 95 ◦C, 5 s Tm, and 26 s 72 ◦C (measurement of fluorescence).
Melting curve analysis (10 s 95 ◦C, 60 s 65 ◦C, and 1 s 97 ◦C) was performed directly after PCR run.
Relative gene expression was calculated using the 2−∆∆CT method.
4.2.5. Glucose Uptake Assay
The effects of the synthesized substance on glucose uptake were evaluated using the
Glucose Uptake Cell-Based Assay Kit (Cayman chemicals, Ann Arbor, MI, USA) and two
different methods. (a) Plate reader-based measurement: PC-3 cells (12 × 103 cells/well) were
seeded in two 96-well plates, incubated overnight, and treated with the investigated drugs in
100 µL/well of glucose-free 0.1% FBS/RPMI media for 24 h. Then, the 10 µL/well of either 2-NBDG
solution (2-deoxy-2-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]-d-glucose, 5 mg/mL, for glucose uptake
measurements) or vehicle solution (for cell viability measurements) in glucose-free 0.1% FBS/RPMI
media were added to each well. After 6 h of incubation, the cells were carefully washed twice with PBS
(200 µL/well). Then, for glucose uptake measurements, the 100 µL/well of PBS were added and the
fluorescence was measured using Infinite F200PRO reader (TECAN, Männedorf, Switzerland); or, for
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the cell viability measurements, 100 µL/well of media containing MTS reagent were added to the cells
and viability was measured as described before [54]. Glucose uptake rate was normalized to the cell
viability measured by MTS assay in order to measure the uptake rate exclusively in the viable cells.
(b) FACS-based readout: The experiment was performed as described before [26]. In brief, the PC-3
cells were seeded into 12-well plates and treated with the investigated compounds for 24 h in RPMI
media (glucose-free, 0.1% FBS). The plates were then incubated with 2-NBDG solution, the cells were
harvested by trypsination, washed, stained with PI, and analyzed using a flow cytometry.
4.2.6. Analysis of Cell Cycle Progression and DNA Fragmentation
The effects on cell cycle progression and DNA fragmentation were analyzed by flow cytometry
using PI staining as described previously [55]. Cells (2 × 105 cells/well) were pre-incubated overnight
in 6-well plates. Then, cells were treated with the substances in 2 mL of fresh culture media/well for
48 h. Cells were harvested by trypsination, fixed in 70% EtOH, stained with PI, and analyzed by FACS
Calibur (BD Bioscience, San Jose, CA, USA). The results were quantified using BD Bioscience Cell
Quest Pro v.5.2.1. software (BD Bioscience, San Jose, CA, USA). The sub-G1 population was considered
to reflect apoptotic cells (containing fragmented DNA).
4.2.7. Analysis of Apoptosis (Annexin-V-FITC/PI Double Staining)
To examine induction of drug-induced apoptosis FACS-based analysis with Annexin-V-FITC and
propidium iodide (PI) double staining was performed as previously described [56,57]. Cells were
seeded in 6-well plates (2 × 105 cells/well) and incubated overnight. Treatment with the substances was
performed in 2 mL fresh culture media/well for 48 h. Cells were harvested by trypsination, stained with
Annexin-V-FITC and PI for 15 min, and analyzed using FACS Calibur (BD Bioscience, San Jose, CA,
USA). The results were quantified using BD Bioscience Cell Quest Pro v.5.2.1. software (BD Bioscience,
San Jose, CA, USA).
4.2.8. Western Blotting
Cells (106 cells/well) were seeded in Petri dishes (ø 6 cm) and incubated overnight. The cells
were treated with the investigational drugs in fresh culture media (5 mL/dish) for 48 h. Then, cells
were harvested by scratching and lysed in the lysis buffer (1% NP-40, 50 mM Tris-HCl (pH 7.6), 0.88%
NaCl, 0.25% sodium cholate, 1 mM Na3VO4, 0.1 mM PMSF, protease inhibitors cocktail (cOmplete
Mini EDTA-free EASYpacks, Roche, Mannheim, Germany)). Proteins were extracted and diluted
with lysis buffer and loading dye, heated 5 min at 99 ◦C and subjected to electrophoresis in gradient
Mini-PROTEAN® TGX Stain-FreeTM gels (Bio-Rad, Hercules, CA, USA). Proteins were transferred from
gel to 0.2 µm pore PVDF membrane using Trans-Blot® TurboTM RTA Mini PVDF Trans kit (Bio-Rad) and
Trans-Blot® TurboTM Blotting System (Bio-Rad) according to the manufactures protocol. The membrane
was blocked (5% BSA in 0.05% Tween-20/TBS), treated with primary and secondary antibodies, and
the signals were detected using the ECL chemiluminescence system (Thermo Scientific, Rockford, IL,
USA). All procedures were performed according to the manufacturer′s protocols. The antibodies used
are listed in Table 1.
4.2.9. Proteomics
The sample preparation and proceeding, data acquisition and analysis have been described
previously [26]. In brief, 22Rv1 cells (4 × 106 cells/bottle in 20 mL/bottle) were seeded and incubated in
T75 culture bottles overnight. Then, the cells were treated 2 µM of SAB-13 or equal volume with vehicle
(DMSO) for 48 h. Treatment was performed in triplicates. Cells were harvested by scratching, washed
with ice-cold PBS (2 × 10 mL) and flash-frozen. The samples were further proceeded (for details,
see [26]) and digested by trypsin. Peptides were separated on a 25 cm C18 reversed phase column
(BEH C18 Column, 130Å, 1.7 µm, 75 µm × 250 mm, Waters Corporation, Milford, MS, USA) within
a 60 min gradient from 2%–30% acetonitrile (equilibration buffer: 0.1% formic acid; elution buffer:
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99.9% acetonitrile and 0.1% formic acid) buffer at a flow rate of 250 nL/min using a nano-UPLC system
(Acquity, Waters Corporation, Milford, MS, USA) and full recovery autosampler vials, coupled via
electrospray ionization (ESI) to a tandem mass spectrometer equipped with a quadrupole and an
orbitrap (QExactive, Thermo Fisher Scientific, Bremen, Germany), using MS/MS mode in DDA (data
dependent acquisition) and DIA (data independent acquisition). The peptide library necessary for DIA
analysis was generated by DDA-LC-MS/MS of 1 randomly selected sample per biological triplicate.
The peptides were identified with the search engine Sequest (integrated in the Proteome Discoverer
software version 2.0, Thermo Fischer Scientific) using the human Uniprot protein database (EMBL;
Hinxton Cambridge, UK, release December 2018). All samples were acquired in DIA mode and data
extraction with the peptide library was performed using the Skyline software (version 4.2, MacCoss
Lab Washington University, Seattle, WA, USA). Peptides with a dot-product (dotP) of 0.85 and above
were considered for further analysis and the peptide areas were summed to protein areas. Statistical
analysis (data normalization, Student′s t-tests, principal component analysis, hierarchical clustering)
was performed using the Perseus software (version 1.5.8, Max-Planck Institute of Biochemistry, Munich,
Germany). Proteins were considered to be significantly different in abundance if a 1.5≤ fold change≤ 1/1.5
and p-value ≤ 0.05 was detected (Student′s t-test).
4.2.10. Bioinformatical Analysis
Bioinformatical analysis of the proteomics data was performed using the Ingenuity Pathways
Analysis (IPA) (release 46901286, QIAGEN Bioinformatics, Venlo, The Netherlands). The list of
significantly regulated proteins discovered by global proteome analysis were proceeded by IPA
software to access protein interaction networks, gene ontology, relevant biological molecules, and
processes affected by the drug, as previously described [58]. The shortest hypothetical pathway
networks were constructed, showing the most relevant direct and indirect interactions of the regulated
proteins and the proteins predicted to be involved in the interactions. z-Score algorithm was used to
identify biological functions which are expected to be suppressed (z-score < 0) or activated (z-score > 0)
upon treatment in cancer cells. The p-values were calculated by IPA software using the Fischer′s exact
test according to the software′s protocols.
4.2.11. Analysis of Intracellular ROS Level
Intracellular ROS levels were accessed using the ROS-sensitive CM-H2DCFDA reagent (Cat. No.
C6827, Molecular probes, Invitrogen, Eugene, OR, USA). The experiment was performed as previously
described with slight modifications [59]. In brief, 22Rv1 cells (105 cells/well) were seeded in 12-well
plates and incubated overnight. The media was changed with freshly made pre-warmed staining
solution (4 µM CM-H2DCFDA/PBS, 0.5 mL/well) and incubated in the dark (37 ◦C, 5% CO2) for
30 min. Then, the staining solution was exchanged with 1 mL/well of pre-warmed PBS containing the
investigated compounds or H2O2 (positive control) at the indicated concentrations and the cells were
incubated for 2 h. Next, the cells were trypsinized, resuspended in pre-warmed PBS (200 µL/sample)
and immediately analyzed by FACS according to the manufacture′s protocol.
4.2.12. Analysis of Mitochondrial Membrane Potential (∆Ψm)
The drop down of mitochondrial membrane potential (∆Ψm) was measured using staining with
∆Ψm-sensitive JC-1 dye (5,5′,6,6′-Tetrachloro-1,1′,3,3′-tetraethyl-imidacarbocyanine iodide) and flow
cytometry technique. Cells (105 cells/well) were seeded in 12-well plates and incubated overnight.
Then, the media was changed to PBS (1 mL/well) containing the investigational drugs and the cells
were incubated for 2 h (37 ◦C, 5% CO2, in the dark). The cells were trypsinized, pelleted, resuspended
in 100 µL of 2 µM JC-1/PBS, incubated for 1 h (37 ◦C, 5% CO2, in the dark), and analyzed by flow
cytometry technique.
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4.2.13. Cell Fractionation
The separation of cellular nuclear, mitochondrial, and cytosolic fractions was performed using
the Cell Fractionation Kit ab109719 (abcam, Cambridge, MA, USA). 22Rv1 cells (4 × 106 cells/bottle)
were seeded in T75 culture bottles (in 20 mL/bottle) and incubated overnight. Cells were treated for
48 h and harvested by scratching. Further procedures were performed as previously described with
slight modifications [59]. Nuclear fractions were homogenized using QIAshedder kit (QUIAGEN,
Hilden, Germany). Cytosolic and mitochondrial fractions were concentrated using Amicon® Ultra-2
Centrifugal Filter device (Cat. No. UFC203024, Merck, Darmstadt, Germany).
4.2.14. Data and Statistical Analysis
For statistical analyses of all the datasets (apart from proteomics data), the GraphPad Prism
software v. 7.05 was used (GraphPad Prism software Inc., La Jolla, CA, USA). Data are presented
as mean ± SEM. The unpaired Student′s t-test or one-way ANOVA followed by Dunnett′s post-hoc
tests were used for comparison of two or several groups, correspondently. Dunnett′s post-hoc test
was used to compare each of a number of a multiple treatment with a single control. All experiments
were performed in in triplicates (n = 3, biological replicates) unless otherwise stated. Differences were
considered to be statistically significant (*) if p < 0.05.
5. Conclusions
We were able to synthesize novel 6-S-(1,4-naphthoquinone-2-yl)-d-glucose chimera molecules,
the derivatives of the sea urchin pigments spinochromes. The compounds exhibited a Warburg
effect mediated selectivity to human prostate cancer cells (including highly drug resistant cell lines)
and effectively inhibited the oxidative phosphorylation. Mitochondria were identified as a primary
cellular target of these compounds. The mechanism of action included mitochondrial membrane
permeabilization, followed by ROS upregulation and release of cytotoxic mitochondrial proteins
(AIF and cytochrome C) to the cytoplasm, which lead to the consequent caspase-9 and -3 activation,
PARP cleavage and apoptosis-like cell death.
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